Emerging therapies for the prevention or treatment of postmenopausal osteoporosis

Journal of Medicinal Chemistry

Volumn 42, Issue 1, 1999, Pages 1-24

  Sato, Masahiko ^a   Grese, Timothy A ^a   Dodge, Jeffrey A ^a   Bryant, Henry U ^a   Turner, Charles H ^b  

^a ELI LILLY AND COMPANY   (United States)

^b INDIANA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(4' PYRROLIDINOETHOXYPHENYL)PHENYL 6 HYDROXY 1,2,3,4 TETRAHYDRONAPTHALENE DEXTRO TARTRATE; 1,1,2 TRIPHENYLETHYLENE DERIVATIVE; 4 (1,2 DIPHENYL 1 BUTENYL)CINNAMIC ACID; 4 [4 METHYL 2 [4 [2 (1 PIPERIDINYL)ETHOXY]PHENYL] 7 PIVALOYLOXY 2H 1 BENZOPYRAN 3 YLPHENYL] PIVALATE; ALENDRONIC ACID; ARZOXIFENE; BENZOPYRAN DERIVATIVE; BENZOTHIOPHENE DERIVATIVE; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CENTCHROMAN; CITRATE CALCIUM; CONJUGATED ESTROGEN; ESTROGEN; FLUORIDE SODIUM; INCADRONIC ACID; IPRIFLAVONE; NAFOXIDINE; NAPHTHALENE DERIVATIVE; OD 14; OSATERONE ACETATE; PARATHYROID HORMONE DERIVATIVE; PARATHYROID HORMONE RELATED PROTEIN; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; RS 23581; SALCATONIN; SDZ PTS 893; TAMOXIFEN CITRATE; TIBOLONE; TILUDRONIC ACID; TOREMIFENE; TRIOXIFENE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZERANOL; ZM 189154;

BONE DENSITY; BONE MASS; BRAIN; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DUAL ENERGY X RAY ABSORPTIOMETRY; ESOPHAGITIS; ESTROGEN THERAPY; EXERCISE; FEMALE; FRACTURE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; MORPHOMETRICS; NONHUMAN; ORAL DRUG ADMINISTRATION; OSTEOLYSIS; PHOTON ABSORPTIOMETRY; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; TRANSDERMAL DRUG ADMINISTRATION;

EID: 0033552889     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm980344o     Document Type: Review

References (382)

1. Frost, H. M. Remodeling dynamics. In Bone Remodeling Biodynamics; Frost, H. M., Ed.; Little Brown: Boston, 1963; pp 65-78.
2. Parfitt, A. M. Quantum concept of bone remodeling and turnover: implications for the pathogenesis of osteoporosis. Calcif. Tissue Int. 1979, 28, 1-5.
3. Kanis, J. A.; Melton, L. J., III; Christiansen, C.; Jonston, C. C.; Khalaev, N. The diagnosis of osteoporosis. J. Bone Miner. Res. 1994, 9, 1137-41.
4. Kanis, J. A.; Devogelaer, J. P.; Gennari, C. Practical guide for the use of bone mineral measurements in the assessment of treatment of osteoporosis: a position paper of the European Foundation for Osteoporosis and Bone Disease. Osteoporosis Int. 1996, 6, 256-261.
5. Hui, S. L.; Slemenda, C. W.; Johnston, C. C., Jr. Age and bone mass as predictors of fracture in a prospective study. J. Clin. Invest. 1988, 81, 1804-9.
6. Slemenda, C. W.; Hui, S. L.; Longcope, C.; Wellman, H.; Johnston, C. C., Jr. Predictors of bone mass in perimenopausal women, a prospective study of clinical data using photon absorptiometry. Ann. Intern. Med. 1990, 112, 96-101.
7. Marshall, D.; Johnell, O.; Wedel, H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. Br. Med. J. 1996, 312, 1254-1259.
8. Melton, L. J., III; Chrischilles, E. A.; Cooper, C.; Lane, A. W.; Riggs, B. L. How many women have osteoporosis? J. Bone Miner. Res. 1992, 7, 1005-1010.
9. Eddy, D.; Cummings, S. R.; Dawson-Hughes B. Guidelines for the prevention, diagnosis and treatment of osteoporosis: Cost-effectiveness analysis and review of the evidence. Osteoporosis Int., in press.
10. Johnell, O.; Gullberg, B.; Allander, E.; Kanis, J. A. The apparent incidence of hip fractures in Europe: A study of national register sources. Osteoporosis Int. 1992, 2, 298-302.
11. Cummings, S. R.; Nevitt, M. C.; Browner, W. S.; Stone, K.; Fox, K. M.; Ensrud, K. E.; Cauley, J.; Black, D.; Vogt, T. M. Risk fractors for hip fracture in white women. N. Engl. J. Med. 1995, 332, 767-773.
12. Barrett-Connor, E. The economic and human costs of osteoporotic fracture. Am. J. Med 1995, 98 (Suppl. 2A), 3S-8S.
13. (a) Melton, L. J., III. Epidemiology of spinal osteoporosis. Spine 1997, 22 (Suppl. 24S), 2s-11s.
14. (b) Nevitt, M. C.; Ettinger, B.; Black, D. M.; Stone, K.; Jamal, S. A.; Ensrud, K.; Segal, M.; Genant, H. K.; Cummings, S. R. The association of radiographically detected vertebral fractures with back pain and function: a prospective study. Ann. Intern. Med. 1998, 128, 793-800.
15. Cooper, C.; Campion, G.; Melton, L. J. Hip fractures in the elderly: A worldwide projection. Osteoporosis Int. 1992, 2, 285-289.
16. Kanis, J. A.; McCloskey, E. V. Evaluation of the risk of hip fracture. Bone 1996, 18 (Suppl. 3), 127s-132s.
17. Schneider, E. L.; Guralnik, J. M. The aging of America. JAMA, J. Am. Med. Assoc. 1990, 263, 2335-40.
18. Cummings, S. R., Rubin, S. M., Black, D. The future of hip fractures in the United States: Numbers, costs, and potential effects of postmenopausal estrogen. Clin. Orthop. 1990, 252, 163-6.
19. Kimmel, D. Animal models for in vivo experimentation in osteoporosis research. Osteoporosis; Marcus, R., Feldman, D., Kelsey, J., Ed.; Academic Press: San Diego, 1996; pp 671-690.
20. Mitlak, B. H.; Sato, M. Bone mineral measurements by DXA in animals. In Methods in Bone Biology; Arnett, T. R., Henderson, B., Eds.; Chapman & Hall: London, 1998; pp 273-289.
21. Turner, C. H.; Burr, D. B. Basic biomechanical measurements of bone: a tutorial. Bone 1993, 14, 595-608.
22. Turner, R. T.; Vandersteenhoven, J. J.; Bell, N. H.; The effects of ovariectomy and 17β estradiol on cortical bone histomorphometry in growing rats. J. Bone Miner. Res. 1987, 2, 115-122.
23. Wronski, T. J.; Cintron, M.; Doherty, A. L.; Dann, L. M. Estrogen treatment prevents osteopenia and depresses bone turnover in ovariectomized rats. Endocrinology 1988, 123, 681-686.
24. Durbridge, T. C.; Morris, H. A.; Parsons, A. M.; Parkinson, I. H.; Moore, R. J.; Porter, S.; Need, A. G.; Nordin, B. E. C.; VernRoberts, B. Progressive cancellous bone loss in rats after adrenalectomy and oophorectomy. Calcif. Tissue Int. 1990, 47, 383-387.
25. Wronski, T. H.; Yen, C. F.; Burton, K. W.; Mehta, R. C.; Newman, P. S.; Soltis, E. E.; DeLuca, P. P. Skeletal effects of calcitonin on ovariectomized rats. Endocrinology 1991, 129, 2246-2250.
26. Seedor, J. G.; Quartuccio, H. A.; Thompson, D. D. The bisphosphonate alendronate (MK-217) inhibits bone loss due to ovariectomy in rats. J. Bone Miner. Res. 1991, 6, 339-346.
27. Toolan, B. C.; Shea, M.; Myers, E. R.; Borchers, R. E.; Seedor, J. G.; Quartuccio, H.; Rodan, G.; Hayes, W. C. Effects of ABP on bone biomechanics in rats. J. Bone Miner. Res. 1992, 12, 1399-1406.
28. Turner, R. T.; Wakley, G. K.; Hannon, K. S.; Bell, N. H. Tamoxifen inhibits osteoclast mediated resorption of trabecular bone in ovarian hormone deficient rats. Endocrinology 1988, 122, 1146-1150.
29. Kalu, D. N.; Salerno, E.; Liu, C. C.; Echon, R.; Ray, M.; Garza-Zapata, M.; Hollis, B. W. A comparative study of the actions of tamoxifen, estrogen and progesterone in the ovariectomized rat. Bone Miner. 1991, 15, 109-124.
30. Moon, L. Y.; Wakley, G. K.; Turner, R. T. Dose-dependent effects of tamoxifen on long bones in growing rats: Influence of ovarian status. Endocrinology 1991, 129, 1568-1574.
31. Black, L. J.; Sato, M.; Rowley, E. R.; Magee, D. E.; Bekele, A.; Williams, D. C.; Cullinan, G. J.; Bendele, R.; Kauffman, R. F.; Bensch, W. R.; Frolik, C. A.; Termine, J. D.; Bryant, H. U. Raloxifene (LY139481 HCl) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J. Clin. Invest. 1994, 72, 63-69.
32. Sato, M.; McClintock, C.; Kim, J.; Turner, C.; Bryant, H.; Magee, D.; Slemenda, C. Dual-energy X-ray absorptiometry of raloxifene effects on the lumbar vertebrae and femora of ovariectomized rats. J. Bone Miner. Res. 1994, 9, 715-724.
33. Sato, M.; Kim, J.; Short, L. L.; Slemenda, C. W.; Bryant, H. U. Longitudinal and cross-sectional analysis of raloxifene effects on tibiae from ovariectomized aged rats. J. Pharmacol. Exp. Ther. 1995, 272, 1252-1259.
34. Sato, M.; Rippy, M. K.; Bryant, H. U. Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats. FASEB J. 1996, 10, 905-912.
35. Sato, M.; Bryant, H.; Iversen, P.; Helterbrand, J.; Smietana, F.; Bemis, K.; Higgs, R.; Owan, I.; Takano, T.; Burr, D. Advantages of raloxifene over alendronate or estrogen on Nonreproductive and reproductive tissues in the long-term dosing of ovariectomized rats. J. Pharmacol. Exp. Ther. 1996, 279, 298-305.
36. Turner, C. H.; Akhter, M. P.; Heaney, R. P. The effects of fluoridated water on bone strength. J. Orthop. Res. 1992, 10, 581-587.
37. Sogaard, C. H.; Mosekile, L.; Schwartz, W.; Leidig, G.; Minne, H. W.; Ziegler, R. Effects of fluoride on rat vertebral body biomechanical competence and bone mass. Bone 1995, 76, 163-169.
38. Jerome, C. P.; Turner, C. H.; Lees, C. J. Decreased bone mass and strength in ovariectomized Cynomolgus monkeys (Macaca fascicularis). Calcif. Tissue Int. 1997, 60, 265-270.
39. Thompson, D. D.; Seedor, J. G.; Quartuccio, H.; Solomon, H.; Fioravanti, C.; Davidson, J.; Klein, H.; Jackson, R.; Clair, J.; Frankenfield, D.; Brown, E.; Simmons, H. A.; Rodan, G. A. The bisphosphonate, alendronate, prevents bone loss in ovariectomized baboons. J. Bone Miner. Res. 1992, 7, 951-960.
40. Balena, R.; Toolan, B. C.; Shea, M.; Markatos, A.; Myers, E. R.; Lee, S. C.; Opas, E. E.; Seedor, J. G.; Klein, H.; Frankenfield, D.; Quartuccio, H.; Fioravanti, C.; Clair, J.; Brown, E.; Hayes, W. C.; Rodan, G. A. The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates J. Clin. Invest. 1993, 92, 2577-2586.
41. Kasra, M.; Grynpas, M. Effect of long-term ovariectomy on bone mechanical properties in young female cynomolgus monkeys. Bone 1994, 15, 557-561.
42. Lundon, K.; Dumitriu, M.; Grynpas, M. The long-term effect of ovariectomy on the quality and quantity of cancellous bone in young macaques. Bone Miner. 1994, 24, 135-149.
43. Jerome, C. P.; Lees, C. J.; Weaver, D. S. Development of osteopenia in ovariectomized cynomolgus monkeys (Macaca fascicularis). Bone 1995, 17 (Suppl. 4), 403S-408S.
44. Burr, D. B. Estimated intracortical bone turnover in the femur of growing macaques: implications for the use as models in skeletal pathology. Anat. Rec. 1992, 232, 180-189.
45. Parfitt, A. M.; Drezner, M. K.; Glorieux, F. H.; Kanis, J. A.; Malluche, H.; Meunier, P. J.; Ott, S. M.; Recker, R. R. Bone histomorphometry: standardization of nomenclature, symbols, and units. J. Bone Miner. Res. 1987, 2, 595-610.
46. Hagiwara, S.; Yang, S. O.; Gluer, C. C.; Bendavid, E.; Genant, H. K. Noninvasive bone mineral density measurement in the evaluation of osteoporosis. Osteoporosis 1994, 20, 651-669.
47. Genant, H. K.; Lang, T. F.; Engelke, K.; Fuerst, T.; Gluer, C. C.; Majumdar, S.; Jergas, M. Advances in the noninvasive assessment of bone density, quality, and structure. Calcif. Tissue Int. 1996, 59 (Suppl. 1), S10-S15.
48. Turner, C. H.; Peacock, M.; Timmerman, L.; Neal, J. M.; Johnston, C. C. Calcaneal ultrasonic measurements discriminate hip fracture independently of bone mass. Osteoporosis Int. 1995, 5, 130-135.
49. Bouxsein, M. L.; Courtney, A. C.; Hayes, W. C. Ultrasound and densitometry of the calcaneus correlate with the failure loads of cadaveric femurs. Calcif. Tissue Int. 1995, 56, 99-103.
50. Heaney, R. P.; Kanis, J. A. The interpretation and utility of ultrasound measurements of bone. Bone 1996, 18, 491-2.
51. Lane, N. E.; Thompson, J. M.; Strewler, G. J.; Kinney, J. H. Intermittent treatment with human parathyroid hormone (hPTH-[1-34]) increased trabecular bone volume but not connectivity in osteopenic rats. J. Bone Miner. Res. 1995, 10, 1470-1477.
52. Ruegsegger, P.; Koller, S.; Muller, R. Amicrotomographic system for the nondestructive evaluation of bone architecture. Calcif. Tissue Int. 1996, 58, 24-29.
53. Schiessl, H.; Ferretti, J. L.; Tysarczyk-Niemeyer, G.; Willnecker, J. Noninvasive bone strength index as analyzed by peripheral quantitative computed tomography (pQCT). In Paediatric osteology: new developments in diagnostics and therapy, Schonau, E., Ed.; Elsevier Science B.V.: Amsterdam, 1996; pp 141-146.
54. Helterbrand, J. D.; Higgs, R. E.; Iversen, P. W.; Tysarczyk-Niemeyer, G.; Sato, M. Application of autormatic image segmentation to tibiae and vertebrae from ovariectomized rats. Bone 1997, 21, 401-409.
55. Westerlind, K. C.; Wronski, T. J.; Ritman, E. L.; Luo, Z. P.; An, K. N.; Bell, N. H.; Turner, R. T. Estrogen regulates the rate of bone turnover but bone balance in ovariectomized rats is modulated by prevailing mechanical strain. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 4199-4204.
56. Einhorn, T. Bone stength: The bottom line. Calcif. Tissue Int. 1992, 51, 333-339.
57. Martin, R. B. Aging and strength of bone as a structural material. Calcif. Tissue Int. 1993, 53 (Suppl. 1), S34-S40.
58. Longcope, C.; Franz, C.; Morello, C.; Baker, R.; Johnston, C. C. Steroid and gonadotropin levels in women during the perimenopausal years. Maturitas 1986, 8, 189-196.
59. Turner, R. T.; Riggs, B. L.; Spelsberg, T. C. Skeletal effects of estrogen. Endocr. Rev. 1994, 75, 275-300.
60. Kuiper, G. G.; Enmark, E.; Pelto-Huikko, M.; Nilsson, S.; Gustafsson, J. A. Cloning of a novel receptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 5925-5930. Kuiper, G. G.; Carlsson, B.; Grandien, K.; Enmark, E.; Haggblad, J.; Nilsson, S.; Gustafsson, J. A. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β. Endocrinology 1997, 138, 863-870.
61. Kuiper, G. G.; Enmark, E.; Pelto-Huikko, M.; Nilsson, S.; Gustafsson, J. A. Cloning of a novel receptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 5925-5930. Kuiper, G. G.; Carlsson, B.; Grandien, K.; Enmark, E.; Haggblad, J.; Nilsson, S.; Gustafsson, J. A. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β. Endocrinology 1997, 138, 863-870.
62. Anderson, J. M.; Peck, E. J.; Clark, J. Nuclear receptor estrogen complex: relationship between concentration and early uterotrophic responses. Endocrinology 1973, 92, 1488-1495.
63. Higgins, S. J.; Rousseau, G.; Baxter, J.; Tompkins, G. Nature of nuclear acceptor sites for glucocorticoid and estrogen receptor complexes. J. Biol. Chem. 1973, 248, 5873-5881.
64. Komm, B. S.; Terpening, C.; Benz, D.; Graeme, K.; Gallegos, A.; Korc, M.; Greene, G. L.; O'Malley, B. W.; Haussler, M. R. Estrogen binding, receptor mRNA, and biologic response in osteoblast-like osteosarcoma cells. Science 1988, 241, 81-84.
65. Eriksen, E.; Colvard, D.; Berg, N.; Graham, M.; Mann, K.; Spelsberg, T. C.; Riggs, B. L. Evidence of estrogen receptors in normal human osteoblast-like cells. Science 1988, 241, 84-87.
66. Etienne, M.; Fischel, J. L.; Milano, G.; Formento, P.; Formento, J. L.; Faucoual, M.; Fenoy, M.; Maner, M. Steroid receptors in human osteoblast-like cells. Eur. J. Cancer 1990, 26, 807-810.
67. Ikegami, A.; [noue, S.; Hosoi, T.; Mizuno, Y.; Nakamura, T.; Ouchi, Y.; Orimo, H. Immunohistochemical detection and northern blot analysis of estrogen receptor in osteoblastic cells. J Bone Miner. Res. 1993, 8, 1103-1109.
68. Ciocca, D. R.; Roig, L. M. V. Estrogen receptors in human nontarget tissues: biological and clinical implications. Endocr. Rev. 1995, 16, 35-62.
69. Onoe, Y.; Miyaura, C.; Ohta, H.; Nozawa, S.; Suda, T. Expression of estrogen receptor β in rat bone. Endocrinology 1997, 138, 4509-4512.
70. Burch, J. C.; Byrd, B. F.; Vaughn, W. K. The effects of long-term estrogen on hysterectomized women. Am. J. Obstet. Gynecol. 1974, 118, 778-782.
71. Lindsay, R.; Hart, D. M.; Aitken, J. M.; MacDonald, E. B.; Anderson, J. B.; Clark, A. C. Long-term prevention of postmenopausal osteoporosis by estrogen: evidence for an increased bone mass after delayed onset of estrogen treatment. Lancet 1976, 1, 1038-41.
72. Weiss, N. S.; Ure, C. L.; Ballard, J. H.; Williams, A. R.; Daling, J. R. Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen. N. Engl. J. Med. 1980, 303, 1195-1198.
73. Lindsay, R; Hart, D. M.; Forrest, C.; Baird, C. Prevention of spinal osteoporosis in oopherectomized women. Lancet 1980, 2, 1151-1154.
74. Quigley, M. E. T.; Martin, P. L.; Curnier, A. M.; Brooks, P. Estrogen therapy arrests bone loss in elderly women. Am. J. Obstet. Gynecol. 1987, 156, 1516-1523.
75. Moore, M.; Bracker, M.; Sartoris, D. Long-term estrogen replacement therapy in postmenopausal women sustains vertebral bone mineral density. J. Bone Miner. Res. 1990, 5, 659-664.
76. Lindsay, R.; Tohme, J. F. Estrogen treatment of patients with established postmenopausal osteoporosis. Obstet. Gynecol. 1990, 76, 290-295.
77. Cauley, J. A.; Seeley, D. G.; Ensrud, K.; Ettinger, B.; Black, D.; Cummings, S. R. Estrogen replacement therapy and fractures in older women. Ann. Intern. Med. 1995, 122, 9-16.
78. Bush, T. L.; Wells, H. B.; James, M. K.; Barrett, Connor E.; Marcus, R.; Greendale, G. Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/ progestin interventions (PEPI) trial. JAMA, J. Am. Med. Assoc. 1996, 276, 1389-1396.
79. Schneider, K. L.; Barrett-Connor, E. L.; Morton, M. A. Timing of postmenopausal estrogen for optimal bone mineral density. JAMA, J. Am. Med. Assoc. 1997, 277, 543-547.
80. Hammond, C. B.; Jelovsek, F. R.; Lee, K. L.; Creasman, W. T.; Parker, R. T. Effects of long-term estrogen therapy. I. Metabolic effects. Am. J. Obstet. Gynecol. 1979, 133, 525-536.
81. Stampfer, M. J.; Colditz, G. A.; Willet, W. C.; Manson, J. E.; Rosner, B.; Speizer, F. E.; Hennekens, C. H. Postmenopausal estrogen therapy and cardiovascular disease: Ten-year follow-up from the nurses' health study. N. Engl. J. Med. 1991, 325, 756-762. Grady, D., Rubin, S. M., Petitti, D. B. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann. Intern. Med. 1992, 117, 1016-1037.
82. Stampfer, M. J.; Colditz, G. A.; Willet, W. C.; Manson, J. E.; Rosner, B.; Speizer, F. E.; Hennekens, C. H. Postmenopausal estrogen therapy and cardiovascular disease: Ten-year follow-up from the nurses' health study. N. Engl. J. Med. 1991, 325, 756-762. Grady, D., Rubin, S. M., Petitti, D. B. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann. Intern. Med. 1992, 117, 1016-1037.
83. Devor, M.; Barrett-Conner, E.; Renvall, M.; Feigal, D.; Ramsdell, J. Estrogen replacement therapy and the risk of venous thrombosis. Am. J. Med. 1992, 92, 275-282.
84. (a) Lip, F. Y. H.; Beevers, G.; Zarifis, J. Hormone replacement therapy and cardiovascular risk: the cardiovascular physicians viewpoint. J. Intern. Med. 1995, 238, 389-399.
85. (b) The Writing Group for the PEPI trial. Effects of estrogen or estrogen/ progestin regimens on heart disease risk factors in postmenopausal women. JAMA, J. Am. Med. Assoc. 1995, 273, 199-208.
86. Grodstein, F.; Stampfer, M. J.; Colditz, G. A.; Willett, W. C.; Manson, J. E.; Joffe, M.; Rosner, B.; Fuchs, C.; Hankinson, S. E.; Hunter, D. J.; Hennekens, C. H.; Speizer, F. E. Postmenopausal hormone therapy and mortality. New Eng. J. Med. 1997, 336, 1769-1822.
87. (a) Hulley, S.; Grady, D.; Bush, T.; Furberg, C.; Herrington, D.; Riggs, B.; Vittinhoff, E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA, J. Am. Med. Assoc. 1998, 280, 605-613.
88. (b) Petitti, D. B. Hormone replacement therapy and heart disease prevention: experimentation trumps observation. JAMA, J. Am. Med. Assoc. 1998, 280, 650-652.
89. Ziel, H. K.; Finkle, W. D. Increased risk of endometrial carcinoma among users of conjugated estrogens. N. Engl. J. Med. 1975, 293, 1167-1170.
90. Smith, D. C.; Prentice, R.; Thompson, D. J.; Herrmann, W. L. Association of exogenous estrogen and endometrial carcinoma. N. Engl. J. Med. 1975, 293, 1164-1167.
91. Vesey, M. P. Exogenous hormones in the aetiology of cancer in women. J. R. Soc. Med. 1984, 77, 542-549.
92. Steinberg, K. K.; Thacker, S. B.; Smith, S. C. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA, J. Am. Med. Assoc. 1991, 265, 1985-1990.
93. Dupont, W. D.; Page, D. L. Menopausal estrogen replacement therapy and breast cancer. Arch. Int. Med. 1991, 151, 67-72.
94. Stanford, J. L. The benefits of hormone replacement therapy outweigh the breast-cancer risks for some women. J. Natl. Inst. Health Res. 1996, 8, 40-44.
95. Colditz, G. A. The benefits of hormone replacement therapy do not outweigh the increased risk of breast cancer. J. Natl. Inst. Health. Res. 1996, 8, 41-44.
96. Gibaldi, M. Prevention and treatment of osteoporosis: does the future belong to hormone replacement therapy? J. Clin. Pharmacol. 1997, 37, 1087-1099.
97. Genant, H. K.; Lucas, J.; Weiss, S.; Akin, M.; Emkey, R. Lowdose esterified estrogen therapy: Effects on bone, plasma estradiol concentrations, endometrium and lipid levels. Arch. Intern. Med. 1997, 157, 2609-2615.
98. Lindsay, R.; Hart, D. M.; Clark, B. M. The minimum effective dose of estrogen for prevention of postmenopausal bone loss. Obstet. Gynecol. 1984, 63, 759-763.
99. Lufkin, E. G.; Wahner, H. W.; O'Fallon, W. M.; Hodgson, S. F.; Kotowicz, M. A.; Lane, A. W. Ann. Intern. Med. 1992, 117, 1-9.
100. Connell, E. B. Transdermal estrogen therapy. Postgrad. Med. 1997, 101 (6), 115-116, 122, 128-130.
101. Bhavnani, B. R.; Woolever, C. A. Interaction of ring B unsaturated estrogens with estrogen receptors of human endometrium and rat uterus. Steroids 1991, 56, 201.
102. Washburn, S. A.; Adams, M. R.; Clarkson, T. C.; Adelman, S. J. A conjugated equine estrogen with differential effects on uterine weight and plasma cholesterol in the rat. Am. J. Obstet. Gynecol. 1993, 169, 251.
103. Washburn, S. A.; Lewis, C. E.; Johnson, J. E.; Voytko, M. L.; Shively, C. A. 17α-dihydroequilenin increases hippocampal dendritic spine density of ovariectomized rats. Brain Res. 1997, 758, 241.
104. Dodge, J. A.; Magee, D. E.; Shetler, P.; Cole, H.; Adrian, D.; Bryant, H. U. Premarin components: uterine, cholesterol lowering and bone metabolic effects. 10th Int. Congr. Endocrinol. 1996, P1-249.
105. Wilcox, J. G.; Hwang, J.; Hodis, H. N.; Sevanian, A.; Stanczyk, F. Z.; Lobo RA. Cardioprotective effects of individual conjugated equine estrogens through their possible modulation of insulin resistance and oxidation of low-density lipoprotein. Fertil. Steril. 1997, 67, 57-62.
106. Kneifel, M. A.; Leytus, S. P.; Fletcher, E.; Weber, T.; Mangel, W. F.; Katzenellenbogen, B. A. Uterine plasminogen activator activity: modulation by steroid hormones. Endocrinology 1982, 111, 493.
107. Lemon, L. H. Pathophysiologic considerations in the treatment of menopausal patients with oestrogen: the role of oestriol in the prevention of mammery carcinoma. Acta Endocrinol. Supp. 1980, 233, 17-27.
108. Fotsis, T; Zhang, Y.; Pepper, M. S.; Adlercreutz, H.; Montesano, R.; Nawroth, P. P.; Schweigerer, L. The endogenous estrogen metabolite 2-methoxyestradiol inhibits tubulin angiogenesis and suppresses tumor growth. Nature 1994, 268, 237.
109. Cushman, M.; He, H-M.; Katzenellenbogen, J. A.; Varma, R. K.; Hamel, E.; Lin, C, M.; Ram, S.; Sachdeva, Y. P. Synthesis of analogues of 2-methoxyestradiol and enhanced inhibitory effects of tubulin polymerization and cancer cell growth. J. Med. Chem. 1997, 40, 2323.
110. Mueller, G. P.; Johns, W. F.; Cook, D. L.; Edgren, R. A. 16α-chloro and 16α-iodoestrone methyl ether, new and potent lipid-shifting agents. J. Am. Chem. Soc. 1958, 80, 1769-1770.
111. Chinn, L. J.; Dygos, J H.; Mares, S. E.; Aspinall, R. L.; Ranney, R. E. 9,11-Seco Steroids. An attempt to separate biological activities via ring cleavage. J. Med. Chem. 1974, 17, 351.
112. Dygos, J. H.; Chinn, L. J. Synthesis of 9,11-secoestradiol 3-methyl ether. J. Org. Chem. 1975, 40, 685.
113. Lippuner, K.; Haenggi, W.; Birkhaeuser, M. H. Casez, J. P.; Jaeger, P. Prevention of postmenopausal bone loss using tibolone or conventional peroral or transdermal hormone replacement therapy with 17beta-estradiol and dydrogesterone. J. Bone Miner. Res. 1997, 12 (5), 806-12.
114. Tax, L.; Goorissen, E. M.; Kicovic, P. M. Clinical profile of Org OD 14. Maturitas 1987, Suppl. 1, 3-13.
115. Fuse, H.; Fukumoto, S.; Sone, H.; Miyata, Y.; Saito, T.; Nakayama, K.; Takahashi, H.; Matsumoto, T.; Ogata, E. A new synthetic steroid, osaterone acetate (TZP-4238), increases cortical bone mass and strength by enhancing bone formation in ovariectomized rats. J. Bone Miner. Res. 1997, 12, 590-597.
116. Wagner, J. D.; Cefalu, W. T.; Anthony, M. S.; Litwak, K. N.; Zhang, L.; Clarkson, T. B. Dietary Soy Protein and Estrogen Replacement Therapy Improve Cardiovascular Risk Factors and Decrease Aortic cholesteryl ester content in ovariectomized cynomologus monkeys. Metabolism 1997, 46, 698-705.
117. Goodman, M. T.; Wilkens, L. R.; Hankin, J. H.; Lyu, L. C.; Wu, A. H.; Kolonel, L. N. Association of soy and fiber consumption with the risk of endometrial cancer Am. J. Epidemiol. 1997, 146, 294-305.
118. Dodge, J. A.; Glasebrook, A. L.; Magee, D. E.; Phillips, D. L.; Sato, M.; Short, L. L.; Bryant, H. U. Environmental estrogens: effects on cholesterol lowering and bone in the ovx rat. J. Steroid. Biochem. Molec. Biol. 1996, 59, 155-161.
119. Tsutsumi, N. The effect of coumestrol on bone metabolism in organ culture. Biol. Pharm. Bull. 1995, 18, 1012-1015.
120. Gradishar, W. J.; Jordan, V. C. Clinical potential of new antiestrogens. J. Clin. Oncol. 1997, 15, 840-852.
121. Jordan, V. C.; MacGregor, J. I.; Tonetti, D. A. Tamoxifen: from breast cancer therapy to the design of a postmenopausal prevention maintenance therapy. Osteoporosis Int. 1997, 7 (Suppl. 1), S52-7.
122. Grese, T. A.; Dodge, J. A. Selective estrogen receptor modulators (SERMs). J. Med. Chem., in press.
123. Willson, T. M.; Norris, J. D.; Wagner, B. L.; Asplin, I.; Baer, P.; Brown, H. R.; Jones, S. A.; Henke, B.; Sauls, H.; Wolfe, S.; Morris, D. C.; McDonnell, D. P. Dissection of the molecular mechanism of action of GW5638, a novel estrogen receptor ligand, provides insights into the role of estrogen receptor in bone. Endocrinology 1997, 138 (9), 3901-3911.
124. Love, R. R.; Mazess, R. B.; Barden, H. S.; Epstein, S.; Newcomb, P. A.; Jordan, V. C.; Carbone, P. P.; DeMets, D. L. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N. Engl. J. Med. 1992, 326, 852-856.
125. Sunderland, M. C.; Osborne, C. K. Tamoxifen in premenopausal patients with metastatic breast cancer: a review. J. Clin. Oncol. 1991, 9, 1283-1297.
126. Love, R. R.; Cameron, L.; Cornell, B. L.; Leventhal, H. Symptoms associated with tamoxifen treatment in postmenopausal women. Arch. Int. Med. 1991, 151, 1842-1847.
127. Chander, S. K.; Sahota, S. S.; Evans, T. R. J.; Luqmani, Y. A. The biological evaluation of novel anti-estrogens for the treatment of breast cancer. Crit. Rev. Oncol. Hematol. 1993, 15, 243-269.
128. Magarian, R. A.; Overacre, L. B.; Singh, S.; Meyer, K. L. The medicinal chemistry of nonsteroidal antiestrogens: a review. Curr. Med. Chem. 1994, 1, 61-104.
129. Fisher, B.; Dignam, J.; Bryant, J.; DeCillis, A.; Wickerham, D. L.; Wolmark, N.; Costantino, J.; Redmond, C.; Fisher, E. R.; Bowman, D. M.; Deschenes, L.; Dimitrov, N. V.; Margolese, R. G.; Robidoux, A.; Shibata, H.; Terz, J.; Paterson, A. H. G.; Feldman, M. I.; Farrar, W.; Evans, J.; Lickley, H. L. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J. Natl. Cancer Inst. 1996, 88, 1529-1542.
130. Kedar, R. P.; Bourne, T. H.; Powles, T. J.; Collins, W. P.; Ashley, S. E.; Cosgrove, D. O.; Cambell, S. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomized breast cancer prevention trial. Lancet 1994, 343, 1318-1321.
131. Kuo, D. Y. S.; Runowicz, C. D. Gynecologic effects of tamoxifen. Med. Oncol. 1995, 12, 87-94.
132. Robinson, D. C.; Bloss, J. D.; Schiano, M. A. A retrospective study of tamoxifen and endometrial cancer in breast cancer patients. Gynecol. Oncol. 1995, 59, 186-190.
133. Assikis, V. J.; Neven, P.; Jordan, V. C.; Vergote, I. A realistic clinical perspective of tamoxifen and endometrial carcinogenesis. Eur. J. Cancer 1996, 32A, 1464-1476.
134. Osborne, M. R.; Hewer, A.; Hardcastle, I. R.; Carmichael, P. L.; Phillips, D. H. Identification of the major tamoxifen-deoxyguanosine adduct formed in the liver DNA of rats treated with tamoxifen. Cancer Res. 1996, 56, 66-71.
135. Hemminki, K.; Rajaniemi, H.; Lindahl, B.; Moberger, B. Tamoxifen-induced DNA adducts in endometrial samples from breast cancer patients. Cancer Res. 1996, 56, 4374-4377.
136. Williams, G. M.; Iatropoulos, M. J.; Djordjevic, M. V.; Kaltenberg, O. The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat. Carcinogenesis 1993, 14, 315-317.
137. Di Salle, E.; Zaccheo, T.; Ornati, G. Antiestrogenic and antitumor properties of the new triphenylethylene derivative toremifene in the rat. J Steroid Biochem. 1990, 36, 203-206.
138. White, I. N. H.; de Matteis, F.; Davies, A.; Smith, L. L.; Crofton-Sleigh, C.; Venitt, S.; Hower, A.; Phillips, D. H. I. Genotoxic potential of tamoxifen and analogues in female Fischer F344/n rats, DBA/2 and C57BL/6 mice and in human MCL-5 cells. Carcinogenesis 1992, 13, 2197-2203.
139. Dahme, E. G.; Rattel, B. J. Cancer Res. Clin. Oncol. 1992, 118 (Suppl. 1), R172.
140. Wiseman, L. R.; Goa, K. L. Toremifene. A review of its pharmacological properties and clinical efficacy in the management of advanced breast cancer. Drugs 1997, 54, 141-160.
141. Rauschning, W.; Pritchard, K. I. Droloxifene, a new antiestrogen: its role in metastatic breast cancer. Breast Cancer Res. Treat. 1994, 37, 83-94.
142. Johnston, S. R. D.; Riddler, S.; Haynes, B. P.; Hern, R. A.; Smith, I. E.; Jarman, M.; Dowsett, M. The novel anti-oestrogen idoxifene inhibits the growth of human MCF-7 breast cancer xenografts and reduces the frequency of acquired anti-oestrogen resistance. Br. J. Cancer 1997, 75, 804-809.
143. Toko, T.; Shibata, J.; Nukatsuka, M.; Yamada, Y. Antiestrogenic activity of DP-TAT-59, an active metabolite of TAT-59 against human breast cancer. Cancer Chemother. Pharmacol. 1997, 39, 390-398.
144. Brewster, M. E.; Paran, Y.; Rushkin, E.; Biegen, A; Pop, E.; Degani, H. Evaluation of the anticancer action of a permanently charged tamoxifen derivative, tamoxifen methiodide: an MRI study. Int. J. Pharm. 1997, 153, 147-157.
145. Niikura, K.; Nakajima, Y.; Nishio, M.; Nakayama, O.; Kojo, H.; Notsu, Y.; Ono, T. Effects of droloxifene on bone mineral content in rat models. Jpn. J. Pharmacol. 1992, 58 (Suppl. 1), 361.
146. Ke, H. Z.; Chen, H. K.; Simmons, H. A.; Qi, H.; Crawford, D. T.; Pine, C. M.; Chidsey-Frink, K. L.; Ma, Y. F.; Jee, W. S. S.; Thompson, D. D. Comparative effects of droloxifene, tamoxifen, and estrogen on bone, serum cholesterol, and uterine histology in the ovariectomized rat model. Bone 1997, 20, 31-39.
147. Tomas, E.; Kauppila, A.; Blanco, G.; Apaja-Sarkkinen, M.; Laatikainen, T. Comparison between the effects of tamoxifen and toremifene on the uterus in postmenopausal breast cancer patients. Gynecol. Oncol. 1995, 59, 261-266.
148. Hayes, D. F.; Van Zyl, J. A.; Hacking, A.; Goedhals, L.; Bezwoda, W. R.; Mailliard, J. A.; Jones, S. E.; Vogel, C. L.; Berris, R. F.; Shemano, I.; et al. Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J. Clin. Oncol. 1995, 13, 2556-66.
149. Pyrhonen, S.; Valavaara, R.; Modig, H.; Pawlicki, M.; Pienkowski, T.; Gundersen, S.; Bauer, J.; Westman, G.; Lundgren, S.; Blanco, G.; Mella, O.; Nilsson, I.; Hietanen, T.; Hindy, I.; Vuorinen, J.; Hajba, A. Comparison of toremifene and tamoxifen in postmenopausal patients with advanced breast cancer: a randomized double-blind, the 'nordic' phase III study. Br. J. Cancer 1997, 76, 270-7.
150. Gershanovich, M.; Garin, A.; Baltina, D.; Kurvet, A.; Kangas, L.; Ellmen, J. A phase III comparison of two toremifene doses to tamoxifen in postmenopausal women with advanced breast cancer. Eastern European Study Group. Breast Cancer Res. Treat. 1997, 45, 251-62.
151. Chen, H. K.; Ke, H. Z.; Lin, C. H.; Ma, Y. F.; Qi, H.; Crawford, D. T.; Pine, C. M.; Simmons, H. A.; Jee, W. S. S.; Thompson, D. D. Droloxifene inhibits cortical bone turnover associated with estrogen deficiency in rats. Bone 1995, 17, 175S-179S.
152. Chen, H. K.; Ke, H. Z.; Jee, W. S. S.; Ma, Y. F.; Pirie, C. M.; Simmons, H. A.; Thompson, D. D. Droloxifene prevents ovariectomy-induced bone loss in tibiae and femora of aged female rats: a dual-energy X-ray absorptiometric and histomorphometric study. J. Bone Miner. Res. 1995, 10, 1256-1262.
153. Ke, H. Z.; Simmons, H. A.; Pirie, C. M.; Crawford, D. T.; Thompson, D. D. Droloxifene, a new estrogen antagonist/agonist, prevents bone loss in ovariectomized rats. Endocrinology 1995, 136, 2435-2441.
154. Buzdar, A. U.; Marcus, C.; Holmes, F.; Hug, V.; Hortobagyi, G. Phase II evaluation of Ly156758 in metastatic breast cancer. Oncology 1988, 45, 344-5.
155. (a) Delmas, P. D.; Bjarnason, N. H.; Mitlak, B. H.; Ravoux, A. C.; Shah, A. S.; Huster, W. J.; Draper, M.; Christiansen, C. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N. Engl. J. Med. 1997, 337, 1641.
156. (b) Ettinger, B.; Black, D.; Cummings, S.; Genant, H.; Gluer, C.; Lips, P.; Knickerbocker, R.; Eckert, S.; Nickelsen, T.; Mitlak, B. Raloxifene reduces the risk of incident vertebral fractures: 24-month interim analyses. Osteoporosis Int. 1998, 8 (Suppl. 3).
157. Adrian, M. D.; Cole, H. W.; Shetler, P. K.; Rowley, E. R.; Magee, D. E.; Pell, T.; Zeng, G. Q.; Sato, M.; Bryant, H. U. Comparative pharmacology of a series of selective estrogen receptor modulators. J. Bone Miner. Res. 1996, 11 (Suppl. 1), T590.
158. Ashby, J.; Odum, J.; Foster, J. R. Activity of raloxifene in immature and ovariectomized rat uterotrophic assays. Reg. Toxicol. Pharmacol. 1997, 25, 226-31.
159. Grese, T. A.; Sluka, J. P.; Bryant, H. U.; Cullinan, G. J.; Glasebrook, A. L.; Jones, C. D.; Matsumoto, K.; Palkowitz, A. D.; Sato, M.; Termine, J. D.; Winter, M. A.; Yang, N. N.; Dodge, J. A. Molecular determinants of selectivity in estrogen receptor modulators. Proc. Natl. Acad. Sci. USA, 1997, 94, 14105-14110.
160. McCague, R.; Jarman, M.; Leung, O. T.; Foster, A. B.; Leclercq, G.; Stoessel, S. Nonisomeisable antiestrogens related to tamoxifen. J. Steroid Biochem. 1988, 31, 545-548.
161. Brzozowski, A. M.; Pike, A. C. W.; Dauter, Z.; Hubbard, R. E.; Monn, T.; Engström, O.; Öhman, L.; Greene, G. L.; Gustafsson, J.-Å.; Carlquist, M. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997, 389, 753-757.
162. Grese, T. A.; Sluka, J. P.; Bryant, H. U.; Cole, H. W.; Kim, J. R.; Magee, D. E.; Rowley, E. R.; Sato, M. Benzopyran selective estrogen receptor modulators (SERMs): pharmacological effects and structural correlation with raloxifene. Bioorg. Med. Chem. Lett. 1996, 6, 903-908.
163. Rosati, R. L.; Da Silva Jardine, P.; Cameron, K. O.; Thompson, D. D.; Ke, H. Z.; Toler, S. M.; Brown, T. A.; Pan, L. C.; Ebbinghaus, C. F.; Reinhold, A. R.; Elliot, N. C.; Newhouse, B. N.; Tjoa, C. M.; Sweetnam, P. M.; Cole, M. J.; Arriola, M. W.; Gauthier, J. W.; Crawford, D. T.; Nickerson, D. F.; Pirie, C.; Qi, H.; Simmons, H. A.; Tkalcevic, G. T. Discovery and SAR of a potent nonsteroidal estrogen agonist CP-336,156. J. Bone Miner. Res. 1996, 11 (Suppl. 1), S447.
164. Sato, M.; Turner, C. H.; Wang, T.; Adrian, M. D.; Bryant, H. U. LY353381.HC1: A novel raloxifene analogue with improved SERM potency and efficacy in vivo. J. Pharmacol. Exp. Ther., in press.
165. Lednicer, D.; Babcock, J. C.; Lyster, S. C.; Duncan, W. G. Derivatives of 1,2-diphenyl-3,4-dihydronaphthalene as antifertility agents. Chem. Ind. (London) 1963, 408-409.
166. Dukes, M.; Chester, R.; Yarwood, L.; Wakeling, A. E. Effects of a nonsteroidal pure antioestrogen, ZM 189,154, on oestrogen target organs of the rat including bones. J. Endocrinol. 1994, 141, 335-341.
167. Jones, C. D.; Suarez, T.; Massey, E. H.; Black, L. J.; Tinsley, F. C.
168. Ke, H. Z.; Paralkar, V. M.; Grasser, W. A.; Crawford, D. T.; Qi, H.; Simmons, H. A.; Pirie, C. M.; Chidsey-Fink, K. L.; Owen, T. A.; Smock, S. L.; Chen, H. K.; Jee, W. S. S.; Cameron, K. O.; Rosati, R. L.; Brown, T. A.; Di Silva, Jardine, P.; Thompson, D. D. Effects of CP-336,156, a new, nonsteroidal estrogen agonist/ antagonist, on bone, serum cholesterol, uterus and body composition in rat models. Endocrinology 1998, 139, 2068-2076.
169. Bain, S. D.; Celino, D. L.; Baily, M. C.; Strachan, M. J.; Piggott, J. R.; Labroo, V. M. Centchroman, a nonsteroidal antiestrogen, is a bone-specific estrogen agonist in the ovariectomized rat. Calcif. Tissue Int. 1995, 54, 338.
170. Trivedi, R. N.; Chauhan, S. C.; Dwivedi, A.; Kamboj, V. P.; Singh, M. M. Time-related effects of a triphenylethylene antiestrogen on estrogen-induced changes in uterine weight, estrogen receptors, and endometrial sensitivity in rats. Contraception 1995, 51, 367-379.
171. Nowak, J.; Festersen, U.; Andersen, A.; Christensen, N. D. Effect of levormeloxifene, a partial estrogen receptor agonist, on serum cholesterol, osteocalcin and bone in the ovariectomized rat. J. Bone Miner. Res. 1997, 12 (Suppl. 1), S347.
172. Nowak, J.; Sjogren, I.; Festersen, U.; Christensen, N. D. Effect of levormeloxifene, a partial estrogen receptor agonist, on body weight, food conversion efficacy, and uterus in the ovariectomized rat. J. Bone Miner. Res. 1997, 12 (Suppl. 1), S346.
173. Bain, S. D.; Grennspan, D.; Kurman, R.; Shalmi, M.; Guldhammer, B.; Korsgaard, N. Levormeloxifene, a nonsteroidal, partial estrogen agonist, prevents bone loss, reduces serum cholesterol and exerts a nonproliferative action on uterine tissues in the ovariectomized rat. J. Bone Miner. Res. 1997, 12 (Suppl. 1), S347.
174. Bjarnason, K.; Skrumsager, B. K.; Kiehr, B. Levormeloxifene, a new partial estrogen receptor agonist demonstrates antiresorptive and antiatherogenic properties in postmenopausal women. J. Bone Miner. Res. 1997, 12 (Suppl. 1), S346.
175. Gauthier, S.; Caron, B.; Cloutier, J.; Dory, Y. L.; Favre, A.; Larouche, D.; Mailhot, J.; Quellet, C.; Schwerdtfeger, A.; Leblanc, G. EM800: a highly potent, specific, and orally active nonsteroidal antiestrogen. J. Med. Chem. 1997, 40, 2117-2122. Martel, L. S.; Sourla, C.; Gauthier, S.; Merand, Y.; Belanger, A.; Labrie, C.; Labrie, F. Comparative effects of 28-day treatment with a new anti-estrogen EM-800 and tamoxifen on estrogensensitive parameters in intact mice. Int. J. Cancer 1997, 73, 381-391.
176. Gauthier, S.; Caron, B.; Cloutier, J.; Dory, Y. L.; Favre, A.; Larouche, D.; Mailhot, J.; Quellet, C.; Schwerdtfeger, A.; Leblanc, G. EM800: a highly potent, specific, and orally active nonsteroidal antiestrogen. J. Med. Chem. 1997, 40, 2117-2122. Martel, L. S.; Sourla, C.; Gauthier, S.; Merand, Y.; Belanger, A.; Labrie, C.; Labrie, F. Comparative effects of 28-day treatment with a new anti-estrogen EM-800 and tamoxifen on estrogensensitive parameters in intact mice. Int. J. Cancer 1997, 73, 381-391.
177. Simard, J.; Labrie, C.; Belanger, A.; Gauthier, S.; Singh, S. M.; Merand, Y.; Labrie, F. Characterization of the effects of the novel nonsteroidal antiestrogen EM-800 on basal and estrogen-induced proliferation of T-47D, ZR-75-1 and MCF-7 human breast cancer cells in vitro. Int. J. Cancer 1997, 73, 104-112. Simard, J.; Sanchez, R.; Poirier, D.; Gauthier, S.; Singh, S. M.; Merand, Y.; Belanger, A.; Labrie, C.; Labrie, F. Blockade of the stimulatory effect of estrogens, OH-tamoxifen, OH-toremifene, droloxifene, and raloxifene on alkaline phosphatase activity by the anti-estrogen EM-800 in human endometrial adenocarcinoma Ishikawa cells. Cancer Res. 1997, 57, 3494-3497.
178. Simard, J.; Labrie, C.; Belanger, A.; Gauthier, S.; Singh, S. M.; Merand, Y.; Labrie, F. Characterization of the effects of the novel nonsteroidal antiestrogen EM-800 on basal and estrogen-induced proliferation of T-47D, ZR-75-1 and MCF-7 human breast cancer cells in vitro. Int. J. Cancer 1997, 73, 104-112. Simard, J.; Sanchez, R.; Poirier, D.; Gauthier, S.; Singh, S. M.; Merand, Y.; Belanger, A.; Labrie, C.; Labrie, F. Blockade of the stimulatory effect of estrogens, OH-tamoxifen, OH-toremifene, droloxifene, and raloxifene on alkaline phosphatase activity by the anti-estrogen EM-800 in human endometrial adenocarcinoma Ishikawa cells. Cancer Res. 1997, 57, 3494-3497.
179. McDonnell, D. P.; Clemm, D. L.; Hermann, T.; Goldman, M. E.; Pike, J. W. Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Mol. Endocrinol. 1995, 9, 659-669.
180. Yang, N. N.; Bryant, H. U.; Hardikar, S.; Sato, M.; Galvin, R. J. S.; Glasebrook, A.; Termine, J. D. Estrogen and raloxifene stimulate transforming growth factor-β3 gene expression in rat bone: a potential mechanism for estrogen-or raloxifene-mediated bone maintenance. Endocrinology 1996, 137, 2075-2084.
181. Yang, N. N.; Venugopalan, M.; Hardikar, S.; Glasebrook, A. Identification of an estrogen response element activated by metabolites of 17 β estradiol and raloxifene. Science 1996, 273, 1222-1225. Yang, N. N.; Venugopalan, M.; Hardikar, S.; Glasebrook, A. Correction: raloxifene response needs more than an element. Science 1997, 275, 1249.
182. Yang, N. N.; Venugopalan, M.; Hardikar, S.; Glasebrook, A. Identification of an estrogen response element activated by metabolites of 17 β estradiol and raloxifene. Science 1996, 273, 1222-1225. Yang, N. N.; Venugopalan, M.; Hardikar, S.; Glasebrook, A. Correction: raloxifene response needs more than an element. Science 1997, 275, 1249.
183. Caldwell, B. M.; Watson, R. I. An evaluation of psychologic effects of sex hormone administration in aged women. Results of therapy after six months. J. Gerentol. 1952, 7, 228-244.
184. Paganini-Hill, A.; Henderson, V. S. Estrogen replacement therapy and risk of Alzheimer's disease. Arch. Intern. Med. 1996, 156, 2213-2217.
185. Morrison, A.; Resnick, S.; Corrada, M.; Zonderman, A.; Kawas, C. A. prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease in the Baltimore longitudinal study of aging. Neurology 1996, 46 (Suppl. 2), A435-436.
186. Tang, M. X.; Jacobs, D.; Stern, Y. Effect of oestrogen during menopause on risk and age at onset of Alzheimers disease. Lancet 1996, 348, 429-432.
187. Brenner, D. E.; Kukull, W. A.; Sterrgachis, A. Postemenopausal estrogen replacement therapy and the risk of Alzheimer's disease: A population-based case-controll study. Am. J. Epidemiol. 1994, 140, 262-267.
188. Sherwin, B. B.; Phillips, S. Estrogen and cognitive function in surgically menopausal women. Ann. N.Y. Acad. Sci. 1990, 592, 474-475.
189. Wickelgren, I. Estrogen stakes claim to cognition. Science 1997, 276, 675-678.
190. Li, X.; Schwartz, P. E.; Rissman, E. F. Distribution of estrogen receptor-beta-like immunoreactivity in rat forebrain. Neuroendocrinology 1997, 66, 63-67.
191. Merchenthaler, I.; Lane, L. V.; Shughrue, P. J. The comparative distribution of estrogen receptor (α and β) mRNA-expressing neurons in the rat central nervous system: An in situ hybridization study. Soc. Neurosci. Abs. 1997, 23, 1683.
192. Mermelstein, P. G.; Becker, J. B.; Surmeier, D. J. Estradiol reduces calcium currents in rat neostriatal neurons via a membrane receptor. J. Neurosci. 1996, 16, 595-604.
193. Song, J.; Standley, P. R.; Zhang, F.; Joshi, D.; Gappy, S.; Sowers, J. R.; Ram, J. L. Tamoxifen (estrogen antagonist) inhibits voltage-gated calcium current and contractility in vascular smooth muscle from rats. J. Pharmacol. Exp. Ther. 1996, 277, 1444-53.
194. Lomax, P.; Schonbaum, E. Postmenopausal hot flushes and their management. Pharmacol. Ther. 1993, 57, 347-358.
195. Draper, M. W.; Flowers, D. E.; Huster, W. J.; Neild, J. A.; Harper, K. D.; Arnaud, C. A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women. J. Bone Miner. Res. 1996, 11, 835-842.
196. Love, R. R.; Wiebe, D. A.; Newcomb, P. A.; Cameron, L.; Leventhal, H.; Jordan, V. C.; Feyzi, J.; DeMets, D. L. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann. Intern. Med. 1991, 115, 860-864.
197. Bryant, H. U.; Bales, K. R.; Paul, S. M.; Yang, H.; Cole, H. W.; Walker-Daniels, J.; McEwen, B.; Chow, H.; Santerre, R. E. Estrogen agonist effects of selective estrogen receptor modulators in ovariectomized rat brain. Soc. Neurosci. Abs. 1997, 23, 2377.
198. Fink, G.; Sumner, B. E.; Rosie, R.; Grace, O. and Quinn, J. P. Estrogen control of neurotransmission: Effect on mood, mental state and memory. Cell Molec. Neurobiol. 1996, 16, 325-344.
199. Magos, A. L.; Brewster, E.; Singh, R.; O'Dowd, T.; Brincat, M.; Studd, J. W. The effects of norethistrone in postmenopausal women on oestrogen replacement therapy: A model for the premenstrual syndrome. Br. J. Obstet. Gynecol. 1984, 3, 93-99.
200. Nicholson, G. C.; Moseley, J. M.; Sexton, P. M.; Mendelsohn, G. A. O.; Martin, T. J. Abundant calcitonin receptors in isolated rat osteoclasts. J. Clin. Invest. 1986, 64, 355-360.
201. Arnett, T. R.; Demptser, D. W. A comparative study of disaggregated chick and rat osteoclasts in vitro: Effects of calcitonin and prostaglandins. Endocrinology 1987, 120, 602-608.
202. Murrills, R. J.; Shane, E.; Lindsay, R.; Dempster, D. W. Bone resorption by isolated human osteoclasts in vitro: effects of calcitonin. J. Bone Miner. Res. 1989, 4, 259-268.
203. Raisz, L. G.; Wener, J. A.; Trummel, C. L.; Feinblatt, J. F.; Au, W. Y. W. Induction, inhibition and escape as phenomena in bone resorption. Excerpta Med. Int. Congr. Ser. 1972, 243, 446-449. Tashjian, A. H.; Wright, D. R.; Ivey, J. L.; Pont, A. Calcitonin binding sites in bone: relationships to biological response and "escape". Recent Prog. Horm. Res. 1978, 34, 285-299. Nicholson, G. C.; Moseley, J. M.; Yates, A. J. P.; Martin, T. J. Control of cAMP production in osteoclasts: calcitonin-induced persistent activation and homologous desensitization of adenylate cyclase. Endocrinology 1987, 120, 1902-1908.
204. Raisz, L. G.; Wener, J. A.; Trummel, C. L.; Feinblatt, J. F.; Au, W. Y. W. Induction, inhibition and escape as phenomena in bone resorption. Excerpta Med. Int. Congr. Ser. 1972, 243, 446-449. Tashjian, A. H.; Wright, D. R.; Ivey, J. L.; Pont, A. Calcitonin binding sites in bone: relationships to biological response and "escape". Recent Prog. Horm. Res. 1978, 34, 285-299. Nicholson, G. C.; Moseley, J. M.; Yates, A. J. P.; Martin, T. J. Control of cAMP production in osteoclasts: calcitonin-induced persistent activation and homologous desensitization of adenylate cyclase. Endocrinology 1987, 120, 1902-1908.
205. Raisz, L. G.; Wener, J. A.; Trummel, C. L.; Feinblatt, J. F.; Au, W. Y. W. Induction, inhibition and escape as phenomena in bone resorption. Excerpta Med. Int. Congr. Ser. 1972, 243, 446-449. Tashjian, A. H.; Wright, D. R.; Ivey, J. L.; Pont, A. Calcitonin binding sites in bone: relationships to biological response and "escape". Recent Prog. Horm. Res. 1978, 34, 285-299. Nicholson, G. C.; Moseley, J. M.; Yates, A. J. P.; Martin, T. J. Control of cAMP production in osteoclasts: calcitonin-induced persistent activation and homologous desensitization of adenylate cyclase. Endocrinology 1987, 120, 1902-1908.
206. Kohno, T.; Murasugi, N.; Sakurai, H.; Watabe, K.; Nakamuta; Koida, M.; Sugie, Y.; Nomura, M.; Yanagawa, A. A sandwich transfer enzyme immuno assay for salmon calcitonin: Determination of the bioavailability of intranasal salmon calcitonin in human. J. Clin. Lab Anal. 1997, 11, 380-387.
207. Overgaard, K.; Hansen, M. A.; Jensen, S. B.; Christiansen, C. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis. Br. Med. J. 1992, 305, 556-561.
208. Cardona, J. M.; Pastor, E. Calcitonin versus etidronate for the treatment of postmenopausal osteoporosis: a meta-analysis of published clinical trials. Osteoporosis Int. 1997, 7 (3), 165-74.
209. Thamsborg, G.; Jensen, J. E.; Kollerup, G.; Hauge, E. M.; Melsen, F.; Sorensen, O. H. Effect of nasal salmon calcitonin on bone remodeling and bone mass in postmenopausal osteoporosis. Bone 1996, 18 (2), 207-12.
210. Stock, J. L.; Avioli, L. V.; Baylink, D. J.; Chesnut, C.; Genant, H. K.; Maricic, M. J.; Silver-man, S. L.; Schaffer, A. V.; Feinblatt, J. Calcitonin-salmon nasal spray reduces the incidence of new-vertebral fractures in postmenopausal women: 3 year interim results of the proof study. J. Bone Miner. Res. 1997, 12 (Suppl. 1), S149.
211. Rodan, G.; Fleisch, HA. Bisphosphonates: mechanisms of action. J. Clin. Invest. 1996, 97, 2692-2696. Fleisch, H. Bisphosphonates in Bone Disease: From the Laboratory to the Patient, 3rd ed.; Parthenon Publishing: 1997.
212. Rodan, G.; Fleisch, HA. Bisphosphonates: mechanisms of action. J. Clin. Invest. 1996, 97, 2692-2696. Fleisch, H. Bisphosphonates in Bone Disease: From the Laboratory to the Patient, 3rd ed.; Parthenon Publishing: 1997.
213. Reginster, J. Y. L.; Halkin, V.; Gosset, C.; Deroisy, R. The role of bisphosphonates in the treatment of osteoporosis. Drugs Today 1997, 33, 563-570. Jeal, W.; Barradell, L. B.; McTavish, D. Alendronate: a review of its pharmacological properties and therapeutic efficacy in postmenopausal osteoporosis. Adis Drug Evaluation 1997, 53, 415-434. Yates, J.; Rodan, G. A. Alendronate and osteoporosis. DDT 1998, 3, 69-78.
214. Reginster, J. Y. L.; Halkin, V.; Gosset, C.; Deroisy, R. The role of bisphosphonates in the treatment of osteoporosis. Drugs Today 1997, 33, 563-570. Jeal, W.; Barradell, L. B.; McTavish, D. Alendronate: a review of its pharmacological properties and therapeutic efficacy in postmenopausal osteoporosis. Adis Drug Evaluation 1997, 53, 415-434. Yates, J.; Rodan, G. A. Alendronate and osteoporosis. DDT 1998, 3, 69-78.
215. Reginster, J. Y. L.; Halkin, V.; Gosset, C.; Deroisy, R. The role of bisphosphonates in the treatment of osteoporosis. Drugs Today 1997, 33, 563-570. Jeal, W.; Barradell, L. B.; McTavish, D. Alendronate: a review of its pharmacological properties and therapeutic efficacy in postmenopausal osteoporosis. Adis Drug Evaluation 1997, 53, 415-434. Yates, J.; Rodan, G. A. Alendronate and osteoporosis. DDT 1998, 3, 69-78.
216. Watts, N. B.; Harris, S. T.; Genant, H. K.; Wasnich, R. D.; Miller, P. D.; Jackson, R. D.; Licata, A. A.; Ross, P.; Woodson, G. C.; Yanover, M. J.; Mysiw, J. W.; Kohse, L.; Rao, M. B.; Steiger, P.; Richmond, B.; Chesnut, C. H. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N. Engl. J. Med. 1990, 323, 73-79. Harris, S. T.; Watts, N. B.; Jackson, R. D.; Genant, H. K.; Wasnich, R. D.; Ross, P.; Miller, P. D.; Licata, A. A.; Chesnut, C. H. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am. J. Med. 1993, 95, 557-567.
217. Watts, N. B.; Harris, S. T.; Genant, H. K.; Wasnich, R. D.; Miller, P. D.; Jackson, R. D.; Licata, A. A.; Ross, P.; Woodson, G. C.; Yanover, M. J.; Mysiw, J. W.; Kohse, L.; Rao, M. B.; Steiger, P.; Richmond, B.; Chesnut, C. H. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N. Engl. J. Med. 1990, 323, 73-79. Harris, S. T.; Watts, N. B.; Jackson, R. D.; Genant, H. K.; Wasnich, R. D.; Ross, P.; Miller, P. D.; Licata, A. A.; Chesnut, C. H. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am. J. Med. 1993, 95, 557-567.
218. Jowsey, J.; Riggs, B. L.; Kelly, P. J.; Hoffman, D. L.; Bordier, P. The treatment of osteoporosis with disodium ethane-1-hydroxy-1,1-diphosphonate. J. Lab. Clin. Med. 1971, 78, 574-581. Heaney, R. P.; Saville, P. D. Etidronate disodium in postmenopausal women. Clin. Pharmacol. Ther. 1976, 20, 593-604. Boyce, B. F.; Smith, L.; Fogelman, I.; Johnston, E.; Ralston, S.; Boyle, I. T. Focal osteomalacia due to low-dose diphosphonate therapy in Paget's disease. Lancet 1984, 821-824. Gibbs, C. J.; Aaron, J. E.; Peacock, M. Osteomalacia in Paget's disease treated with short-term, high dose sodium etidronate. Br. Med. J. 1986, 292, 1227-1229.
219. Jowsey, J.; Riggs, B. L.; Kelly, P. J.; Hoffman, D. L.; Bordier, P. The treatment of osteoporosis with disodium ethane-1-hydroxy-1,1-diphosphonate. J. Lab. Clin. Med. 1971, 78, 574-581. Heaney, R. P.; Saville, P. D. Etidronate disodium in postmenopausal women. Clin. Pharmacol. Ther. 1976, 20, 593-604. Boyce, B. F.; Smith, L.; Fogelman, I.; Johnston, E.; Ralston, S.; Boyle, I. T. Focal osteomalacia due to low-dose diphosphonate therapy in Paget's disease. Lancet 1984, 821-824. Gibbs, C. J.; Aaron, J. E.; Peacock, M. Osteomalacia in Paget's disease treated with short-term, high dose sodium etidronate. Br. Med. J. 1986, 292, 1227-1229.
220. Jowsey, J.; Riggs, B. L.; Kelly, P. J.; Hoffman, D. L.; Bordier, P. The treatment of osteoporosis with disodium ethane-1-hydroxy-1,1-diphosphonate. J. Lab. Clin. Med. 1971, 78, 574-581. Heaney, R. P.; Saville, P. D. Etidronate disodium in postmenopausal women. Clin. Pharmacol. Ther. 1976, 20, 593-604. Boyce, B. F.; Smith, L.; Fogelman, I.; Johnston, E.; Ralston, S.; Boyle, I. T. Focal osteomalacia due to low-dose diphosphonate therapy in Paget's disease. Lancet 1984, 821-824. Gibbs, C. J.; Aaron, J. E.; Peacock, M. Osteomalacia in Paget's disease treated with short-term, high dose sodium etidronate. Br. Med. J. 1986, 292, 1227-1229.
221. Jowsey, J.; Riggs, B. L.; Kelly, P. J.; Hoffman, D. L.; Bordier, P. The treatment of osteoporosis with disodium ethane-1-hydroxy-1,1-diphosphonate. J. Lab. Clin. Med. 1971, 78, 574-581. Heaney, R. P.; Saville, P. D. Etidronate disodium in postmenopausal women. Clin. Pharmacol. Ther. 1976, 20, 593-604. Boyce, B. F.; Smith, L.; Fogelman, I.; Johnston, E.; Ralston, S.; Boyle, I. T. Focal osteomalacia due to low-dose diphosphonate therapy in Paget's disease. Lancet 1984, 821-824. Gibbs, C. J.; Aaron, J. E.; Peacock, M. Osteomalacia in Paget's disease treated with short-term, high dose sodium etidronate. Br. Med. J. 1986, 292, 1227-1229.
222. Devogelaer, J. P.; Broll, H.; Correa-Rotter, R.; Cumming, D. C.; De, Deuxchaisnes; C. N.; Geusens, P.; Hosking, D.; Jaeger, P.; Kaufman, J. M.; Leite, M.; Leon, J.; Liberman, U.; Menkes, C. J.; Meunier, P. J.; Reid, I.; Rodriguez, J.; Romanowicz, A.; Seeman, E.; Vermeulen, A.; Hirsch, L. J.; Lombardi, A.; Plezia, K.; Santora, A. C.; Yates, A. J.; Yuan, W. Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis. Bone 1996, 18, 141-150.
223. Black, D. M.; Cummings, S. R.; Karpf, D. B.; Cauley, J. A.; Thompson, D. E.; Nevitt, M. C.; Bauer, D. C. Genant, H. K.; Haskell, W. L.; Marcus, R.; Ott, S. M.; Torner, J. C.; Quandt, S. A.; Reiss, T. F.; Ensrud, K. E. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996, 348 (9041), 1535-41.
224. Liberman, U. A.; Weiss, S. R.; Broll, J.; Minne, H. W.; Dequeker, J.; Favus, M.; Seeman, E.; Recker, R.; Capizzi, T.; Santora, A. C.; Lombardi, A.; Shah, R.; Hirsch, L. J.; Karpf, D. B. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N. Engl. J. Med. 1995, 333, 1437-1443.
225. Hosking, D.; Chilvers, C.; Christiansen, C.; Ravn, P.; Wasnich, R.; Ross, P.; McClung, M.; Balske, A.; Thompson, D.; Daley, M.; Yates, A. J. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. New Engl. J. Med. 1998, 338, 485-492.
226. Chavassieux, P. M.; Ariot, M. E.; Reda, C.; Wei, L.; Yates, A. J.; Meunier, P. J. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J. Clin. Invest. 1997, 100, 1475-1480.
227. Balena, R.; Markatos, A.; Seedor, J. G.; Gentile, M.; Stark, C.; Peter, C. P.; Rodan, G. A. Long-term safety of the aminobisphosphonate alendronate in adult dogs. II. Histomorphometric analysis of the L5 vertebra. J. Pharmacol. Exp. Ther. 1996, 276, 277-283.
228. Sato, M.; Grasser, W.; Endo, N.; Akins, R; Simmons, H.; Thompson, D. D.; Golub, E.; Rodan, G. A. Bisphosphonate action: Alendronate localization in rat bone and effects on osteoclast ultrastructure. J. Clin. Invest. 1991, 69, 2095-2105.
229. Breuil, V.; Cosman F.; Stein, L.; Horbert, W.; Nieves, J.; Shen, V.; Lindsay, R.; Dempster, D. W. Human osteoclast formation and activity in vitro: effects of alendronate. J. Bone Miner. Res., in press.
230. Lin, J. H.; Chen, I. W.; deLuna, F. A. Nonlinear kinetics of alendronate, plasma protein binding and bone uptake. Drug Metab. Dispos. 1994, 22, 400-405. Lin, J. H. Bisphosphonates: A review of their pharmacokinetic properties. Bone 1996, 18, 75-85.
231. Lin, J. H.; Chen, I. W.; deLuna, F. A. Nonlinear kinetics of alendronate, plasma protein binding and bone uptake. Drug Metab. Dispos. 1994, 22, 400-405. Lin, J. H. Bisphosphonates: A review of their pharmacokinetic properties. Bone 1996, 18, 75-85.
232. Lin, J. H.; Chen, I. W.; deLuna, F. A. On the absorption of alendronate in rats. J. Pharm. Sci. 1994, 83, 1741-46.
233. Azuma, Y.; Sato, H.; Oue, Y.; Okabe, K.; Ohta, T.; Tsuchimoto, M.; Kiyoki, M. Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models. Bone 1995, 16, 235-45.
234. Gertz, B. J.; Holland, S. D.; Kline, W. F.; Matuszewski, B. K.; Porras, A. G. Clinical pharmacology of alendronate sodium. Osteoporosis Int. 1993, (Suppl. 3), S13-S16. Fern, E. D.; Vasikaran, S. D.; Khan, S. Sustained suppression of bone resorption after intravenous alendronate in postmenopausal osteoporosis. In Fourth International Symposium of Osteoporosis; Hong Kong, 1993 (abstract).
235. Gertz, B. J.; Holland, S. D.; Kline, W. F.; Matuszewski, B. K.; Porras, A. G. Clinical pharmacology of alendronate sodium. Osteoporosis Int. 1993, (Suppl. 3), S13-S16. Fern, E. D.; Vasikaran, S. D.; Khan, S. Sustained suppression of bone resorption after intravenous alendronate in postmenopausal osteoporosis. In Fourth International Symposium of Osteoporosis; Hong Kong, 1993 (abstract).
236. Sato, M.; Grasser, W. Effects of bisphosphonates on isolated rat osteoclasts as examined by reflected light microscopy. J. Bone Miner. Res. 1990, 5, 31-40.
237. Hughes, D. E.; MacDonald, B. R.; Russell, R. G. G.; Gowen, M. Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J. Clin. Invest. 1989, 67, 1930-1935.
238. Schmidt, A.; Rutledge, S. U.; Endo, N.; Opas, E. E.; Tanaka, H.; Wesolowski, G.; Leu, C. T.; Huang, Z.; Ramachandaran, C.; Rodan, S. B.; Rodan, G. A. Protein-tyrosine phosphatase activity regulates osteoclast formation and function: inhibition by alendronate. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 3068-3073.
239. Hughes, D. E.; Wright, K. R.; Uly, H. L.; Sasaki, A.; Yoneda, T.; Roodman, G. D.; Mundy, G. R.; Boyce, B. F. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J. Bone Miner. Res. 1995, 10, 1478-1487.
240. Sahni, M.; Guenther, H. L.; Fleisch, H.; Collin, P.; Martin, T. J. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J. Clin. Invest. 1993, 71, 2004-11.
241. Owens, J. M.; Fuller, K.; Chambers, T. J. Osteoclast activation: potent inhibition by the bisphosphonate alendronate through a nonresorptive mechanism. J. Cell Physiol. 1997, 172, 79-86.
242. Burr, D. B.; Forwood, M. R.; Fyhrie, D. P.; Martin, R. B.; Schaffler, M. B.; Turner, C. H. Bone microdamage and skeletal fragility in osteoporotic and stress fractures. J. Bone Miner. Res. 1997, 12, 6-15.
243. Gertz, B. J.; Holland, S. D.; Kline, W. F.; Bogdan, K.; Matuszewski, B. K.; Freeman, A.; Porras, A. G. Studies of the oral bioavailability of alendronate. Clin. Pharmacol. Ther. 1995, 58, 288-298.
244. Pizzani, E.; Valenzuela, G. Esophagitis associated with alendronate sodium. Virginia Med. Q. 1997, 124 (3), 181-182.
245. Levine, J.; Nelson, D. Esophageal stricture associated with alendronate therapy. Am. J. Med. 1997, 102 (5), 489-91.
246. Horton, M. A.; Rodan, G. A. Integrins as therapeutic targets in bone. In Adhesion Receptors as Therapeutic Targets, Horton, M. A., Ed.; CRC Press: New York, 1996; pp 223-245.
247. Sato, M. M. K.; Sardana, W. A.; Grasser, V. M.; Garsky, J. M.; Murray, A. H.; Gould, R. J. Echistatin is a potent inhibitor of bone resorption in culture. J. Cell Biol. 1990, 111, 1713-1723.
248. Sato, M. V.; Garsky, R. J.; Majeska, T. A.; Einhorn, J.; Murray, A. H.; Tashjian; Gould, R. J. Structure - activity studies of the s-echistatin inhibition of bone resorption: Implications for therapeutic utility. J. Bone Miner. Res. 1994, 9, 1441-1449.
249. Fisher, J. E.; Caulfield, M. P.; Sato, M.; Quartuccio, H. A.; Gould, R. J.; Garsky, V. M.; Rodan, G. A.; Rosenblatt, M. Inhibition of osteoclastic bone resorption in vivo by echistatin, an arginyl-glycyl-asartyl (RGD)-containing protein. Endocrinology 1993, 132, 1411-1413.
250. Yamamoto, M.; Fisher, J. E.; Gentile, M.; Seedor, J. G.; Leu, C. T.; Rodan, S. B.; Rodan, G. A. The integrin ligand echistatin prevents bone loss in ovariectomized mice and rats. Endocrinology 1998, 139, 1411-9
251. Fisher, J. E.; Caulfield, M. P.; Sato, M.; Quartuccio, H. A.; Gould, R. J.; Garsky, V. M.; Rodan, G. A.; Rosenblatt, M. Response to letter. Endocrinology 1993, 133, 2408.
252. Engleman, V. W.; Nickols, A. G.; Ross, F. P.; Horton, M. A.; Griggs, D. W.; Settle, S. L.; Ruminski, P. G.; Teitelbaum, S. L. A peptidomimetic antagonist of the avB3 integrin inhibits bone resorption in vitro and prevents osteoporosis in vivo. J. Clin. Invest. 1997, 99, 22284-2292.
253. Tezuka, K.; Tezuka, Y.; Maejima, A.; Sato, T.; Nemoto, K.; Kamioka, H.; Hakeda, Y.; Kumegawa, M. Molecular cloning of a possible cysteine proteinase predominantly expressed in osteoclasts. J. Biol. Chem. 1994, 269, 1106-1109.
254. Bossard, M. J.; Tomaszek, T. A.; Thompson, S. K.; Amegadzie, B. Y.; Hannings, C. R.; Jones, C.; Kurdla, J. T.; McNulty D. E.; Drake, F. H.; Gowen, M.; Levy, M. A. Proteolytic activity of human osteoclast cathepsin K. J. Biol. Chem. 1996, 271, 12517-12524.
255. Drake, F. H.; Dodds, R.; Connor, J. I.; Debouck, J.; Richardson, S.; Lee, E.; Rieman, D.; Barthlow, R.; Hastings, G.; Gowen, M. Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts. J. Biol. Chem. 1996, 271, 12511-12516.
256. Gelb, B. D.; Shi, G. P.; Chapman, H. A.; Desnick, R. J. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 1996, 273, 1236-1238.
257. Votta, B. J.; Levy, M. A.; Badger, A.; Bradbeer, J.; Dodds, R. A.; James, I. E.; Thompson, S.; Bossard, M. J.; Carr, T.; Connor, J. R.; Tomaszek, T. A.; Szewczuk, L.; Drake, F. H.; Veber, D. F.; Gowen, M. Peptide aldehyde inhibitors of cathepsin K inhibit bone resorption both in vitro and in vivo. J. Bone Miner. Res. 1997, 12, 1396-1406.
258. Keeling, D. J.; Herslof, M.; Ryberg, D.; Sjogren, S.; Solvell, L. Vacuolar H+-ATPases: targets for drug discovery? Ann. N.Y. Acad. Sci. 1996, 834, 600-608.
259. Williams, S.; Wakisaka, A.; Zeng, Q. Q.; Barnes, J.; Martin, G.; Wechter, W. J.; Liang, C. T. Minocycline prevents the decrease in bone mineral density and trabecular bone in ovariectomized aged rats. Bone 1996, 19 (6), 637-44.
260. Heaney, R. P.; Baylink, D. J.; Johnston, C. C., Jr.; Melton, L. J., 3rd; Meunier, P. J.; Murray, T. M.; et al. Fluoride therapy for vertebral crush fracture syndrome. A status report. Ann. Intern. Med. 1989, 111, 678-680.
261. Farley, J. R.; Wergedal, J. E.; Baylink, D. J. Fluoride directly stimulates proliferation and alkaline phosphatase activity of bone forming cells. Science 1983, 227, 330-332.
262. Hall B. K. Sodium fluoride as an initiator of osteogenesis from embryonic mesenchyme in vitro. Bone 1987, 8, 111-116.
263. Khokher, M. A.; Dandona, P. Fluoride stimulates (3H) thymidine incorporation and alkaline phosphatase production by human osteoblasts. Metabolism 1990, 39, 1118-1121.
264. Kopp, J. B.; Robey, P. G. Sodium fluoride does net increase human bone cell proliferation or protein synthesis in vitro. Calcif. Tissue Int. 1990, 47, 221-226.
265. Chavassieux, P.; Chenu, C.; Valentin-Opran, A.; Delmas, P. D.; Boivin, G.; Chapuy, M. C.; Meunier, P. J. In vitro exposure to sodium fluoride does not modify activity or proliferation of human osteoblastic cells in primary cultures. J. Bone Miner. Res. 1993, 8, 37-44.
266. Einhorn, T. A.; Wakley, G. K.; Linkhart, S.; Rush, E. B.; Maloney, S.; Faierman, E. Incorporation of sodium fluoride into cortical bone does not impair the mechanical properties of the appendicular skeleton in rats. Calcif. Tissue Int. 1992, 51, 127-131.
267. Faccini, J. M. Fluoride and bone. Calcif. Tissue Res. 1969, 3, 1-16.
268. Wolinsky, I.; Simkin, A.; Guggenheim, K. Effects of fluoride on metabolism and mechanical properties of rat bone. Am. J. Physiol. 1972, 223, 46-50.
269. Lafage, M. H.; Balena, R.; Battle, M. A.; Shea, M.; Seedor, J. G.; Klein, H.; Hayes, W. C.; Rodan, G. A. Comparison of alendronate and sodium fluoride effects on cancellous and cortical bone in minipigs. A one year study. J. Clin. Invest. 1995, 95, 2127-2133.
270. Sogaard, C. H.; Mosekile, L.; Thomsen, J. S.; Richards, A.; McOsker, J. E. A comparison of the effects of two anabolic agents (Fluoride and PTH) on ash density and bone strength assessed in an osteopenic rat model. Bone 1997, 20, 439-449.
271. Turner, C. H.; Dunipace, A. J. On fluoride and bone strength (letter). Calcif. Tissue Int. 1993, 53, 289-290.
272. Turner, C. H.; Hasegawa, K.; Zhang, W.; Wilson, M.; Li, Y.; Dunipace, A. J. High fluoride intake causes osteomalacia and diminished bone strength in rats with renal deficiency. Bone, in press.
273. Boivin, G.; Duriez, J.; Chapuy, M-C.; Flautre, B.; Hardouin, P.; Meunier, P. J. Relationship between bone fluoride content and histological evidence of calcification defects in osteoporotic women treated long term with sodium fluoride. Osteoporosis Int. 1993, 3, 204-208.
274. Grynpas, M. D.; Holmyard, D. P.; Pritzker, K. P. H. Bone mineralization and histomorphometry in biopsies of osteoporotic patients treated with fluoride. Cells Mater. 1994, 4, 287-297.
275. Lundy, M. W.; Stauffer, M.; Wergedal, J. E.; Baylink, D. J.; Featherstone, J. D.; Hodgson, S. F.; Riggs, B. L. Histomorphometric analysis of iliac crest bone biopsies in placebo-treated versus fluoride-treated subjects. Osteoporosis Int. 1995, 5, 115-129.
276. Dure-Smith, B. A.; Farley, S. M.; Linkhart, S. G.; Farley, J. R.; Baylink, D. J. Calcium deficiency in fluoride-treated osteoporotic patients despite calcium supplementation. J. Clin. Endocrinol. Metab. 1996, 81, 269-275.
277. Grynpas, M. D.; Rey, C. The effect of fluoride treatment on bone mineral crystals in the rat. Bone 1992, 73, 423-429.
278. Fratzl, P.; Schreiber, S.; Roschger, P.; Lafage, M. H.; Rodan, G.; Klaushofer, K. Effects of sodium fluoride and alendronate on the bone mineral in minipigs: a small-angle X-ray scattering and backscattered electron imaging study. J. Bone Miner. Res. 1996, 11, 248-253.
279. Fratzl, P.; Roschger, P.; Eschberger, J.; Klaushofer, K. Abnormal bone mineralization after fluoride treatment in osteoporosis: a small-angle X-ray scattering study. J. Bone Miner. Res. 1994, 9, 1541-1549.
280. Walsh, W. R.; Labrador, D. P.; Kim, H. D.; Guzelsu, N. The effect of in vitro fluoride ion treatment on the ultrasonic properties of cortical bone. Ann. Biomed. Eng. 1994, 22, 404-415.
281. Catanese, J.; Keaveny, T. M. Role of collagen and hydroxyapatite in the mechanical behavior of bone tissue. J. Bone Miner. Res. 1996, 11, S295.
282. Riggs, B. L.; Hodgson, S. F.; O'Fallon, W. M.; Chao, E. Y. S.; Wahner, H. W.; Muhs, J. M.; Cedel, S. L.; Melton, L. J. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N. Engl. J. Med. 1990, 322, 802-809.
283. Pak, C. Y.; Sakhaee, K.; Adams-Huet, B.; Piziak, V.; Peterson, R. D.; Poindexter, J. R. Treatment of postmenopausal osteoporosis with slow-release sodium fluoride: final report of a randomized controlled trial. Ann. Intern. Med. 1995, 123, 401-408.
284. Meunier, P. J.; Sebert, J. L.; Reginster, J. Y.; et al. Fluoride salts do not better prevent new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: the Favos study. Osteoporosis Int. 1998, 1, 4-12.
285. Kleerekoper, M. Fluoride: the verdict is in, but the controversy lingers. J. Bone Miner. Res. 1996, 11 (5), 565-7.
286. Dempster, D. W.; Cosman, F.; Parisien, M; Shen, V.; Lindsay, R. Anabolic actions of parathyroid hormone on bone. Endocr. Rev. 1993, 14, 690-709.
287. Ibbotson, K. J.; Orcutt, C. M.; D'Souza, S. M.; Paddock, C. L.; Arthur, J. A.; Jankowsky, M. L.; Boyce, R. W. Contrasting effects of parathyroid hormone and insulin-like growth factor I in an aged ovariectomized rat model of postmenopausal osteoporosis. J. Bone Miner. Res. 1992, 7, 425-432.
288. Kimmel, D. B.; Bozzato, R. P.; Kronis, K. A.; Kwong, P.; Recker, R. R. The effect of recombinanat human (1-84) or synthetic human (1-34) parathyroid hormone on the skeleton of adult osteopenic ovariectomized rats. Endocrinology 1993, 132, 1577-1584.
289. Shen, V.; Dempster, D. W.; Birchman, R.; Xu, R.; Lindsay, R. Loss of cancellous bone mass and connectivity in ovariectomized rats can be restored by combined treatment with parathyroid hormone and estradiol. J. Clin. Invest. 1993, 71, 2479-2487.
290. Wronski, T. J.; Yen, C. F.; Dann, L. M. Parathyroid hormone is more effective than estrogen or bisphosphonates for restoration of lost bone mass in ovariectomized rats. Endocrinology 1993, 132, 823-831.
291. Sogaard, C. H.; Wronski, T. J.; McOsker, J. E.; Mosekilde, L. The positive effect of parathyroid hormone on femoral neck bone strength in ovariectomized rats is more pronounced than that of estrogen or bisphosphonates. Endocrinology 1994, 134, 650-657.
292. Li, M.; Wronski, T. J. Response of femoral neck to estrogen depletion and parathyroid hormone in aged rats. Bone 1995, 76, 551-557.
293. Gunness-Hey, M.; Hock, J. M. Increased trabecular bone mass in rats treated with human synthetic parathyroid hormone. Metab. Bone Dis. Rel. Res. 1984, 5, 177-181.
294. Hock, J. M.; Gera, I.; Fonseca, J.; Raisz, L. G. Human parathyroid hormone (1-34) increases bone mass in ovariectomized and orchidectomized rats. Endocrinology 1988, 122, 2899-2904.
295. Kalu, D. N.; Echon, R.; Hollis, B. W. Modulation of ovariectomy-related bone loss by parathyroid hormone in rats. Mech. Aging Develop. 1990, 56, 49-62.
296. Mosekilde, L.; Sogaard, C. H.; Danielsen, C. C.; Torring, O.; Nilsson, M. H. L. The anabolic effects of human parathyroid hormone (hPTH) on rat vertebral bone mass are also reflected in the quality of bone assessed by biomechanical testing: A comparison study between hPTH (1-34) and hPTH (1-84). Endocrinology 1991, 129, 421-428.
297. Mosekilde, L.; Sogaard, C. H.; McOsker, J. E.; Wronski, T. J. PTH has a more pronounced effect on vertebral bone mass and biomechanical competence than anti-resorptive agents (estrogen and bisphosphonates) assessed in sexually mature, ovariectomized rats. Bone 1994, 15, 401-408.
298. Takahashi, H. E.; Tanizawa, T.; Hori, M.; Uzawa, T. Effect of intermittent administration of human parathyroid hormone (1-34) on experimental osteopenia of rats induced by ovariectomy. Cell Mater. 1991, (Suppl. 1), 113-117.
299. Mitlak, B. H.; Williams, D. C.; Bryant, H. U.; Paul, D. C.; Neer, R. M. Intermittent administration of PTH (1-34) increases serum 1,25 dihydroxyvitamin D concentrations and spinal bone density in senile (23 month) rats. J. Bone Miner. Res. 1992, 7, 479-484.
300. Tada, K.; Yamamura, T.; Okumura, H.; Kasai, R.; Takahashi, H. Restoration of axial and appendicular bone volumes by hPTH (1-34) in parathyroidectomized and osteopenic rats. Bone 1990, 11, 163-169.
301. Li, M.; Mosekilde, L.; Sogaard, C. H.; Thomsen, J. S.; Wronski, T. J. Parathyroid hormone monotherapy and cotherapy with antiresorptive agents restore vertebral bone mass and strength in aged ovariectomized rats. Bone 1995, 16, 629-635.
302. Qi, H.; Li, M.; Wronski, T. J. A comparison of the anabolic effects of parathyroid hormone at skeletal sites with moderate and severe osteopenia in aged ovariectomized rats. J. Bone Miner. Res. 1995, 10, 948-955.
303. Sato, M.; Zeng, G. Q.; Turner, C. H. Biosynthetic human PTH (1-34) effects on bone quality in aged ovariectomized rats. Endocrinology 1997, 10, 4330-4337.
304. Liu, C. C.; Kalu, D. N. Human parathyroid hormone (1-34) prevents bone loss and augments bone formation in sexually mature ovariectomized rats. J. Bone Miner. Res. 1990, 5, 973-981.
305. Liu, C. C.; Kalu, D. N.; Salerno, E.; Echone, R.; Hollis, B. W.; Ray, M. Preexisting bone loss associated with ovariectomy in rats is reversed by parathyroid hormone. J. Bone Miner. Res. 1991, 6, 1071-1080.
306. Ejersted, C.; Andreassen, T. T.; Oxlund, H.; Jorgensen, P. H.; Bak, B.; Haggblad, J.; Torring, O.; Nilsson, M. H. L. Human parathyroid hormone (1-34) and (1-84) increase the mechanical strength and thickness of cortical bone in rats. J. Bone Miner. Res. 1993, 8, 1097-1101.
307. Gunness-Hey, M.; Hock, J. M. Anabolic effect of parathyroid hormone on cancellous and cortical bone histology. Bone 1993, 14, 447-452.
308. Oxlund, H.; Ejersted, C.; Andreassen, T. T.; Torring, O.; Nilsson, M. H. Parathyroid hormone (1-34) and (1-84) stimulate cortical bone formation both from periosteum and endosteum. Calcif. Tissue Int. 1993, 53, 394-399.
309. Shen, V.; Dempster, D. W.; Mellish, R. W. E.; Birchman, R.; Horbert, W.; Lindsay, R. Effects of combined and separate intermittent administration of low dose parathyroid hormone fragment (1-34) and 17b-estradiol on bone histomorphometry in ovariectomized rats with established osteopenia. Calcif. Tissue Int. 1992, 50, 214-220.
310. Wronski, T. J.; Yen, C. F. Anabolic effects of parathyroid hormone on cortical bone in ovariectomized rats. Bone 1994, 15, 51-58.
311. Baumann, B. D.; Wronski, T. J. Response of cortical bone to antiresorptive agents and parathyroid hormone in aged ovariectomized rats. Bone 1995, 16, 247-253.
312. Mosekilde, L.; Danielsen, C. C.; Sogaard, C. H.; McOsker, J. E.; Wronski, T. J. The anabolic effects of parathyroid hormone on cortical bone mass, dimensions and strength-assessed in a sexually mature, ovariectomized rat model. Bone 1995, 16, 223-230.
313. Hock, J. M.; Hummert, J. R.; Boyce, R. W.; Fonseca, J.; Raisz, L. G. Resorption is not essential for the stimulation of bone growth by hPTH (1-34) in rats in vivo. J. Bone Miner. Res. 1989, 4, 449-458.
314. Onyia, J. E.; Bidwell, J.; Herring, J.; Hulman, J.; Hock, J. M. In vivo, human parathyroid hormone fragment (hPTH 1-34) transiently stimulates immediate early response gene expression, but not proliferation, in trabecular bone cells of young rats. Bone 1995, 17, 479-84.
315. Schmidt, I. U.; Dobnig, H.; Turner, R. T. Intermittent parathyroid hormone treatment increases osteoblast number, steady-state mRNA levels for osteocalcin. Endocrinology 1995, 136, 5127-5134.
316. Dobnig, H; Turner, R. T. Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. Endocrinology 1995, 136, 3632-3638.
317. Leaffer, D.; Sweeney, M.; Kellerman, L. A.; Avnur, Z.; Krstenansky, J. L.; Vickery, B. H.; Caulfield, J. P. Modulation of osteogenic cell ultrastructure by RS-23481, an analogue of human parathyroid hormone related peptide (1-34) and bovine PTH (1-34). Endocrinology 1995, 136, 3624-3631.
318. Dobnig, H.; Turner, R. T. The effects of programmed administration of human parathyroid hormone fragment (1-34) on bone histomorphometry and serum chemistry in rats. Endocrinology 1997, 138, 4607-4612.
319. Heath, H., III. Primary hyperparathyroidism, hyperparathyroid bone disease, and osteoporosis. In Osteoporosis; Marcus, R., Feldman, D., Kelsey, J., Eds.; Academic Press: New York, 1996; pp 885-897.
320. Reeve, J.; Hesp, R.; Williams, D.; Hulme, P.; Klenerman, L.; Zanelli, J.; Darby, A.; Tregear, G.; Parsons, J. The anabolic effect of low doses of human parathyroid hormone fragment on the skeleton in postmenopausal osteoporosis. Lancet 1976, 1, 1035-1038.
321. Reeve, J.; Meunier, P. J.; Parsons, J. A.; Bernat, M.; Bijvoet, O. L. M.; Courpron, P.; Edouard, C.; Klenerman, L.; Neer, R. M.; Renier, J. C. Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: A multicenre trial. Br. Med. J. 1980, 280, 1340-1344.
322. Hodsman, A. B.; Fraher, L. J.; Ostbye, T.; Adachi, J. D.; Steer, B. M. An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis. J. Clin. Invest. 1993, 71, 1138-48.
323. Finkelstein, J.; Klebanski, A.; Schaefer, E.; Hornstein, M.; Schiff, I.; Neer, R. Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency. N. Engl. J. Med. 1994, 331, 1618-1623.
324. Sone, T.; Fukunaga, M.; Ono, S.; Nishiyama, T. A small dose of human parathyroid hormone (1-34) increased bone mass in the lumbar vertebrae in patients with senile osteoporosis. Miner. Electrolyte Metab. 1995, 21, 232-235.
325. Lindsay, R; Nieves, J. Formica, C.; Henneman, E.; Woelfert, L.; Shen, V.; Dempster, D.; Cosman, F. Randomized controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 1997, 350, 550-555.
326. Slovik, D. M.; Rosenthal, S. I.; Doppelt, S. H.; Potts, J. T.; Daly, M. A.; Campbell, J. A.; Neer, R. M. Restoration of spinal bone in osteoporotic men by treatment with human parathyroid hormone (1-34) and 1,25 dihydroxyvitamin D. J. Bone Miner. Res. 1986, 1, 377-381.
327. Reeve, J. PTH: a future role in the management of osteoporosis? J. Bone Miner. Res. 1996, 11, 440-445.
328. Mosekilde, L.; Danielsen, C. C.; Gasser, J. The effect on vertebral bone mass and strength of long-term treatment with antiresorptive agents (estrogen and calcitonin), human parathyroid hormone (1-38), and combination therapy, assessed in aged ovariectomized rats. Endocrinology 1994, 134, 2126-2134.
329. Jerome, C. P. Anabolic effect of high doses of human parathyroid hormone (1-38) in mature intact female rats. J. Bone Miner. Res. 1994, 9 (6), 933-42.
330. Whitfield, J. F.; Morley, P.; Willick, G.; Langille, R.; Ross, V.; MacLean, S.; Barbier, J. R. Cyclization by a specific lactam increases the ability of human parathyroid hormone (hPTH)-(1-31)NH2 to stimulate bone growth in ovariectomized rats. J. Bone Miner. Res. 1997, 12, 1246-1252.
331. Whitfield, J. F.; Morley, P.; Willick, G. E.; Ross, V.; Langille, R.; MacLean, S.; Barbier, J.; Isaacs, R. J.; Ohannessian-Barry, L. Comparison of the abilities of human parathyroid hormone-(1-31)NH2 and human parathyroid hormone-related protein-(1-31)NH2 to stimulate femoral trabecular hone growth in ovariectomized rats. Calcif. Tissue Int. 1997, 61, 322-326.
332. Hodsman, A. B.; Steer, B. M.; Fraher, L. J.; Drost, D. J. Bone densitometric and histomorphometric responses to sequential human parathyroid hormone (1-38) and salmon calcitonin in osteoporotic patients. Bone Miner. 1991, 14, 67-83.
333. Gasser, J. A.; Gombert, F. O.; Cardnaux, F. SDZ PTS 893, a PTH analogue with improved therapeutic window in skeletally mature rats. J. Bone Miner. Res. 1997, 12 (Suppl. 1), S236.
334. Jerome, C. P.; Obasanjo, I.; Kaplan, K.; Gamse, R. SDZ PTS 893, a novel PTH analogue, increases spinal bone mass in ovariectomized monkeys. J. Bone Miner. Res. 1997, 12 (Suppl. 1), S237.
335. Potts, J. T.; Bringhurst, F. R.; Gardella, T.; Nussbaum, S.; Segre, G.; Kronenberg, H. Parathyroid hormone: physiology, chemistry, biosynthesis, secretion, metabolism, and mode of action. In Endocrinology, 3rd ed., DeGroot, L. J., Ed.; WB Saunders: Philadelphia, PA, 1995; Vol. 2, pp 920-966.
336. Hock, J. M.; Fonseca, J.; Gunness-Hey, M.; Kemp, B. E.; Martin, T. J. Comparison of the anabolic effects of synthetic parathyroid hormone-related protein (PTHrP) 1-34 and PTH 1-34 on bone in rats. Endocrinology 1989, 125, 2022-2027.
337. Weir, E. C.; Terwilliger, G.; Sartori, L.; Insogna, K. L. Synthetic parathyroid hormone-like protein (1-74) is anabolic for bone in vivo. Calcif. Tissue Int. 1992, 51, 30-34.
338. Vickery, B. H.; Avnur, Z.; Cheng, Y.; Chiou, S. S.; Leaffer, D.; Caulfield, J. P.; Kimmel, D. B.; Ho, T.; Krstenansky, J. L. RS-66271, a C-terminally substituted analogue of human parathyroid hormone-related protein (1-34), increases trabecular and cortical bone in ovariectomized, osteopenic rats. J. Bone Miner. Res. 1996, 11, 1943-51.
339. Stewart, A. F. PTHrP (1-36) as a skeletal analbolic agent for the treatment of osteoporosis. Bone 1996, 4, 303-306. Wysolmerski, J. J.; Stewart, A. F. The physiology of parathyroid hormone-related protein: an emerging role as a developmental factor. Annu. Rev. Physiol. 1998, 60, 431-460.
340. Stewart, A. F. PTHrP (1-36) as a skeletal analbolic agent for the treatment of osteoporosis. Bone 1996, 4, 303-306. Wysolmerski, J. J.; Stewart, A. F. The physiology of parathyroid hormone-related protein: an emerging role as a developmental factor. Annu. Rev. Physiol. 1998, 60, 431-460.
341. Gasser, J. A.; Gombert, F. O.; Cardinaux, F. SDZ PTS 893, a PTH-analogue with improved therapeutic window in skeletally mature rats. J. Bone Miner. Res. 1997, 12 (Suppl. 1), S236.
342. Agnusdei, D.; Crepaldi, G.; Isaia, G.; Mazzuoli, G.; Ortolani, S.; Passeri, M.; Bufalino, L.; Gennari, C.; A double blind, placebo-controlled trial of ipriflavone for prevention of postmenopausal spinal bone loss. Calcif. Tissue Int. 1997, 61, 142-7.
343. Notoya, K.; Yoshida, K.; Taketomi, S.; Yamazaki, I.; Kumegawa, M. Inhibitory effect of ipriflavone on pit formation in mouse unfractioned bone cells. Calcif. Tissue Int. 1992, 51, S3-S6.
344. Miyauchi, A.; Notoya, K.; Taketomi, S.; Takagi, Y.; Fujii, Y.; Jinnai, K.; Takahashi, K.; Chihara, K.; Fujita, T. Novel ipriflavone receptors coupled to calcium influx regulate osteoclast differentiation and function. Endocrinology 1996, 137, 3544-3550.
345. Kakai, Y.; Kawase, T.; Nakano, T.; Mikuni-Takagaki, Y.; Saito, S. Effect of ipriflavone and estrogen on the differentiation and proliferation of osteogenic cells. Calcif. Tissue Int. 1992, 51, S11-S15.
346. Adami, S.; Bufalino, L.; Cervetti, R.; Di Marco, C.; Di Munno, O.; Fantasia, L.; Isaia, G. C.; Serni, U.; Vecchiet, L.; Passen, M. Ipriflavone prevents radial bone loss in postmenopausal women with low bone mass over 2 years. Osteoporosis Int. 1997, 7, 119-25.
347. Frost, H. Osteoporoses: their nature and therapeutic targets. In Anabolic Treatments for Osteoporosis; Whitfield, J. F., Morley, P., Eds.; CRC Press: New York, 1997; pp 1-29.
348. Frost, H. M.; Ferretti, J. L.; Jee, W. S. S. Perspectives: some roles of mechanical usage, muscle strength, and the mechanostat in skeletal physiology, disease, and research. Calcif. Tissue Int. 1998, 62, 1-7.
349. Forwood, M. R.; Burr, D. B. Physical activity and bone mass: exercises in futility? Bone Miner. 1993, 21, 89-112.
350. Lohman, T.; Going, S.; Pamenter, R.; Hall, M.; Boyden, T.; Houtkooper, L.; Ritenbaugh, C.; Bare, L.; Hill, A.; Aichin, M. Effects of resistance training on regional and total bone mineral density in premenopausal women: a randomized prospective study. J. Bone Miner. Res. 1995, 10, 1015-1024.
351. Colletti, L. A.; Edwards, J.; Gordon, L.; Shary, J.; Bell, N. H. The effects of muscle building exercise on bone mineral density of the radius, spine and hip in young men. Calcif. Tissue Int. 1989, 45, 12-14.
352. Davee, A. M.; Rosen, C.; Adler, R. A. Exercise patterns and trabecular bone density in college women. J. Bone Miner. Res. 1990, 5, 245-250.
353. Wolman, R. L.; Faulman, L.; Clark, P.; Hesp, R.; Harries, M. G. Different training patterns and bone mineral density of the femoral shaft in elite female athletes. Ann. Rheum. Dis. 1991, 50, 487-489.
354. Jones, H.; Priest, J.; Hayes, W.; Tichenor, C.; Nagel, D. Humeral hypertrophy in response to exercise. J. Bone Jt. Surg. 1977, 59A, 204-207.
355. Bassey, E. J.; Ramsdale, S. J. Weight-bearing exercise and ground reaction forces: A 12-month randomized controlled trial of effects on bone mineral density in healthy postmenopausal women. Bone 1995, 16, 469-476.
356. Friedlander, A. L.; Genant, H. K.; Sadowsky, S.; Byl, N. N.; Gluer, C-C. A two-year program of aerobics and weight training enhances bone mineral density of young women. J. Bone Miner. Res. 1995, 10, 574-585.
357. Heinonen, A.; Kannus, P.; Sievanen, H.; Oja, P.; Pasanen, M.; Rinne, M.; Uusi-Rasi, K.; Vuori, I. Randomized controlled trial of effect of high-impact exercise on selected risk factors for osteoporotic fractures. Lancet 1996, 348, 1343-1347.
358. Heinonen, A.; Sievanen, H.; Kannus, P.; Oja, P.; Vuori, I. Effects of unilateral strength training and detraining of bone mineral mass and estimated mechanical characteristics of the upper limb bones in young women. J. Bone Miner. Res. 1996, 11, 490-501.
359. Snow-Harter, C.; Bouxsein, M. L.; Lewis, B. T.; Carter, D. R.; Marcus, R. Effects of resistance and endurance exercise on bone mineral status of young women: a randomized exercise intervention trial. J. Bone Miner. Res. 1992, 7, 761-769.
360. Teegarden, D.; Lyle, R. M.; Proulx, W. R.; Kern, M. K.; McCabe, G.; Peacock, M.; Johnston, C. C.; Weaver, C. M. Effect of exercise intervention and oral contraceptive use in spine bone mineral density in young women. J. Bone Miner. Res. 1995, 10, S456.
361. Welsh, L.; Rutherford, O. M. Hip bone mineral density is improved by high-impact aerobic exercise in postmenopausal women and men over 50 years. Eur. J. Appl. Physiol. 1996, 74, 511-517.
362. Bertram, J. E., Swartz, S. M. The 'law of bone transformation': a case of crying Wolff? Biol. Rev. 1991, 66, 245-273.
363. Parfitt, A. M. The two faces of growth: benefits and risks to bone integrity. Osteoporosis Int. 1994, 4, 382-398.
364. Rubin, C. T.; Bain, S. D.; McLeod, K. J. Suppression of the osteogenic response in the aging skeleton. Calcif. Tissue Int. 1992, 50, 306-313.
365. Turner, C. H.; Takano, Y.; Owan, I. Aging changes mechanical loading thresholds for bone formation in rats. J. Bone Miner. Res. 1995, 10, 1544-1549.
366. Haapasalo, H.; Kannus, P.; Sievanen, H.; Pasanen, M.; Uusi-Rasi, K.; Heinonen, A.; Oja, P.; Vuori, I. Effect of long-term unilateral activity on bone mineral density of female junior tennis players. J. Bone Miner. Res. 1998, 13, 310-319.
367. Kannus, P.; Haapasalo, H.; Sankelo, M.; Sievanen, H.; Pasanen, M.; Heinonen, A.; Oja, P.; Vuori, I. Effect of starting age of physical activity on bone mass in the dominant arm of tennis and squash players. Ann. Intern. Med. 1995, 123, 27-31.
368. Cavanaugh, D. J., Cann, C. E. Brisk walking does not stop bone loss in postmenopausal women. Bone 1988, 9, 201-204.
369. Nelson, M. E.; Fisher, E. C.; Dilmanian, F. A.; Dallal, G. E.; Evans, W. J. A 1-yr walking program and increased dietary calcium in postmenopausal women: effects on bone. Am. J. Clin. Nutr. 1991, 53, 1305-1311.
370. Sandler, R. B.; Cauley, J. A.; Horn, D. L.; Sashin, D.; Kriska, A. M. The effects of walking on the cross-sectional dimensions of the radius in postmenopausal women. J. Bone Miner. Res. 1987, 41, 65-69.
371. Turner, C. H.; Owan, I.; Takano, Y. Mechanotransduction in bone: role of strain rate. Am. J. Physiol. 1995, 269, E438-E442.
372. O'Connor, J. A.; Lanyon, L. E.; MacFie, J. The influence of strain rate on adaptive bone remodeling. J. Biomechanics 1982, 15, 767-781.
373. Fehling, P. C.; Alekel, L.; Clasey, J.; Rector, A.; Stillman, R. J. A comparison of bone mineral densities among female athletes in impact loading and active loading sports. Bone 1995, 17, 205-210.
374. Taaffe, D. R.; Robinson, T. L.; Snow, C. M.; Marcus, R. High-impact exercise promotes bone gain in well-trained female athletes. J. Bone Miner. Res. 1997, 12, 255-260.
375. Radin, E. L.; Paul, I. L.; Rose, R. M. Role of mechanical factors in pathogenesis of primary osteoarthritis. Lancet 1972, 1, 519-522.
376. Felson, D. T.; Zhang, Y.; Hannan, M. T.; Naimark, A.; Weissman, B.; Aliabadi, P.; Levy, D. Risk factors for incident radiographic knee osteoarthritis in the elderly. Arthritis Rheum. 1997, 40, 728-733.
377. Hayes, W. C.; Myers, E. R.; Robinovitch, S. N.; Van Den, Kroonenberg, A.; Courtney, A. C.; McMahon, T. A. Etiology and prevention of age-related hip fractures. Bone 1996, 18, 77S-86S.
378. Rooks, D. S.; Kiel, D. P.; Parsons, C.; Hayes, W. C. Self-paced resistance training and walking exercise in community-dwelling older adults: effects on neuromotor performance. J. Gerontol. 1997, 52, M161-168.
379. Nakamura, T. Vitamin D for the treatment of osteoporosis. Osteoporosis Int. 1997, 7 (Suppl. 3), S155-S158.
380. Nakamura, T. The importance of genetic and nutritional factors in responses to vitamin D and its analogues in osteoporotic patients. Calcif. Tissue Int. 1997, 60, 119-123.
381. Francis, R. M. Is there a differential response to alfacalcidol and vitamin D in the treatment of osteoporosis? Calcif. Tissue Int. 1997, 60, 111-114.
382. Kanis, J. A.; McCloskey, E. V.; Beneton, M. N. Vitamin D and analogues in renal bone disease and implications for osteoporosis. Osteoporosis Int. 1997, 7 (Suppl. 3), S179-S183.